Welcome to Paid Research Studies




  • Conditions:   Non-myeloablative TCR Alpha/Beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation;   Recurrent Lip and Oral Cavity Carcinoma;   Recurrent Malignant Endocrine Neoplasm;   Recurrent Malignant Female Reproductive System Neoplasm;   Recurrent Malignant Male Reproductive System Neoplasm;   Recurrent Malignant Mesothelioma;   Recurrent Malignant Neoplasm of Multiple Primary Sites;   Recurrent Malignant Oral Neoplasm;   Recurrent Malignant Pharyngeal Neoplasm;   Recurrent Malignant Skin Neoplasm;   Recurrent Malignant Soft Tissue Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Malignant Thyroid Gland Neoplasm;   Recurrent Malignant Urinary System Neoplasm;   Recurrent Melanoma of the Skin;   Refractory Cutaneous Melanoma;   Refractory Malignant Bone Neoplasm;   Refractory Malignant Endocrine Neoplasm;   Refractory Malignant Female Reproductive System Neoplasm;   Refractory Malignant Male Reproductive System Neoplasm;   Refractory Malignant Mesothelioma;   Refractory Malignant Neoplasm of Multiple Primary Sites;   Refractory Malignant Oral Neoplasm;   Refractory Malignant Pharyngeal Neoplasm;   Refractory Malignant Skin Neoplasm;   Refractory Malignant Soft Tissue Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Malignant Thyroid Gland Neoplasm;   Refractory Malignant Urinary System Neoplasm
    Interventions:   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Neoplasm;   Castleman Disease;   Digestive System Carcinoma;   Erdheim-Chester Disease;   Lip and Oral Cavity Carcinoma;   Lymphangioleiomyomatosis;   Malignant Endocrine Neoplasm;   Malignant Female Reproductive System Neoplasm;   Malignant Male Reproductive System Neoplasm;   Malignant Neoplasm;   Malignant Respiratory Tract Neoplasm;   Malignant Thoracic Neoplasm;   Malignant Urinary System Neoplasm;   Mesothelial Neoplasm;   Metastatic Malignant Neoplasm;   Metastatic Urothelial Carcinoma;   Neurofibromatosis Type 2;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Breast Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Digestive System Carcinoma;   Recurrent Female Reproductive System Carcinoma;   Recurrent Male Reproductive System Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Pharyngeal Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Malignant Neoplasm;   Soft Tissue Neoplasm;   Stage III Breast Cancer AJCC v7;   Stage III Pharyngeal Cancer;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Pharyngeal Cancer;   Stage IVA Pharyngeal Cancer;   Stage IVB Pharyngeal Cancer;   Stage IVC Pharyngeal Cancer;   Thyroid Gland Neoplasm
    Interventions:   Biological: Bevacizumab;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Temsirolimus;   Drug: Valproic Acid
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Endocrine Neoplasia Syndromes
    Intervention:   Behavioral: Questionnaires
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Multiple Endocrine Neoplasia
    Intervention:  
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Ipatasertib;   Drug: Fulvestrant;   Drug: Aromatase Inhibitor;   Drug: Palbociclib
    Sponsors:   Massachusetts General Hospital;   Genentech, Inc.
    Recruiting

  • Conditions:   Breast Cancer;   Invasive Breast Cancer
    Interventions:   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Tamoxifen
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Conditions:   Multiple Endocrine Neoplasia;   Pancreatic Neuroendocrine Tumors;   Hyperparathyroidism
    Interventions:   Other: Genome Sequencing;   Other: Data Review
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Behavioral: Education;   Behavioral: Values
    Sponsors:   University of Colorado, Boulder;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Breast Cancer
    Intervention:   Drug: OPC
    Sponsor:   Medical University of South Carolina
    Recruiting

  • Conditions:   Estrogen Receptor Positive Breast Cancer;   Breast Neoplasm;   Metastatic Breast Cancer
    Intervention:   Drug: [18F]FES
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Healthy
    Intervention:  
    Sponsors:   Duke University;   United States Department of Defense
    Recruiting

  • Conditions:   Breast Cancer;   Breast Carcinoma;   Malignant Neoplasm of Breast
    Interventions:   Biological: Mammaglobin-A DNA Vaccine;   Procedure: Optional biopsy
    Sponsors:   Washington University School of Medicine;   Rising Tide Foundation;   United States Department of Defense
    Recruiting

  • Conditions:   Breast Cancer;   Adherence, Medication;   Side Effect
    Intervention:   Behavioral: BETA-Text text messaging intervention
    Sponsor:   Yale University
    Not yet recruiting

  • Conditions:   Breast Cancer;   Cancer of Breast;   Breast Neoplasms;   Cancer of the Breast
    Interventions:   Behavioral: FACT-B;   Drug: Goserelin;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Tamoxifen;   Other: Archived tissue collection
    Sponsors:   Washington University School of Medicine;   Genomic Health®, Inc.
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Ribociclib;   Other: Endocrine therapy
    Sponsors:   Massachusetts General Hospital;   Novartis
    Recruiting

  • Condition:   Breast Cancer
    Intervention:  
    Sponsor:   Myriad Genetic Laboratories, Inc.
    Recruiting

  • Conditions:   Endocrine Tumors;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Breast Cancer
    Intervention:   Behavioral: Mobile phone app + patient navigation
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Not yet recruiting

  • Condition:   Multiple Endocrine Neoplasia
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   Progesterone Receptor Positive Breast Cancer;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
    Interventions:   Other: Telemedicine;   Other: Best Practice;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsor:   Thomas Jefferson University
    Recruiting

  • Conditions:   Breast Cancer;   Adherence, Medication
    Interventions:   Other: STRIDE;   Other: Medication Monitoring Control
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Fulvestrant;   Drug: Debio 1347
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Debiopharm International SA
    Recruiting

  • Condition:   Breast Neoplasm Female
    Interventions:   Behavioral: Prompts to report adherence and symptoms via study app;   Behavioral: Feedback messages
    Sponsors:   Emory University;   National Cancer Institute (NCI);   West Cancer Center;   Vector Oncology
    Recruiting

  • Conditions:   Brain Tumor;   Brain Cancer;   Skull Base Tumor
    Intervention:  
    Sponsor:   Baptist Health South Florida
    Recruiting

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Letrozole;   Drug: Tamoxifen;   Drug: Palbociclib;   Drug: Endocrine Therapy
    Sponsors:   Dana-Farber Cancer Institute;   Pfizer
    Recruiting

  • Conditions:   Advanced Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Multiple Endocrine Neoplasia Type 1;   Neuroendocrine Neoplasm;   Unresectable Carcinoid Tumor
    Interventions:   Drug: Everolimus;   Drug: Lenvatinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Early Breast Cancer
    Intervention:   Other: Endocrine therapy interruption
    Sponsors:   International Breast Cancer Study Group;   Alliance for Clinical Trials in Oncology;   Canadian Cancer Trials Group;   Breast International Group
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Tamoxifen;   Drug: Anastrozole;   Drug: Fulvestrant
    Sponsor:   Priscilla McAuliffe
    Recruiting

  • Condition:   Early Breast Cancer
    Interventions:   Drug: Ribociclib;   Other: Endocrine Therapy
    Sponsors:   Novartis Pharmaceuticals;   Translational Research in Oncology
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Biological: Pembrolizumab (K);   Drug: Placebo (P);   Drug: Paclitaxel (X);   Drug: Doxorubicin hydrochloride (A);   Drug: Epirubicin (E);   Drug: Cyclophosphamide (C);   Drug: Endocrine therapy;   Radiation: Radiation therapy;   Procedure: Surgery
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Adenocarcinoma;   Pancreatic Neoplasms;   Neoplasm, Glandular;   Neoplasms;   Neoplasms Pancreatic;   Digestive System Neoplasm;   Endocrine Gland Neoplasms;   Digestive System Disease;   Pancreatic Diseases;   Endocrine System Diseases
    Interventions:   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Cisplatin;   Drug: Irinotecan
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Breast Cancer;   Solid Tumor
    Interventions:   Drug: GDC-0077;   Drug: Fulvestrant;   Drug: Letrozole;   Drug: Palbociclib;   Drug: Metformin
    Sponsor:   Genentech, Inc.
    Recruiting

  • Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Palbociclib;   Drug: Fulvestrant;   Drug: Avelumab
    Sponsors:   Dana-Farber Cancer Institute;   Pfizer
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands
    Interventions:   Drug: Selumetinib;   Drug: Olaparib
    Sponsors:   M.D. Anderson Cancer Center;   AstraZeneca
    Recruiting

  • Condition:   HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
    Interventions:   Drug: PF-06873600;   Drug: Endocrine Therapy 1;   Drug: Endocrine Therapy 2
    Sponsor:   Pfizer
    Recruiting

  • Conditions:   Self-management Intervention (SM-AET);   General Health Education
    Interventions:   Behavioral: SM-AET;   Behavioral: general health education
    Sponsor:   Duke University
    Recruiting

  • Conditions:   Estrogen Receptor Status;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Postmenopausal;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Alisertib;   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Procedure: Computed Tomography;   Drug: F-18 16 Alpha-Fluoroestradiol;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sarcoma;   Endocrine Tumors;   Neuroblastoma;   Retinoblastoma;   Renal Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Solid Tumors;   Advanced Triple Negative Breast Cancer;   Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer;   Advanced Metastatic Castration-Resistant Prostate Cancer;   Advanced Platinum-Resistant Ovarian Cancer
    Interventions:   Drug: TRX518;   Drug: Cyclophosphamide;   Drug: Avelumab
    Sponsors:   Leap Therapeutics, Inc.;   Pfizer;   Merck KGaA, Darmstadt, Germany
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole;   Drug: Goserelin;   Drug: Leuprolide
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Advanced or Metastatic ER+ Breast Cancer
    Interventions:   Drug: LSZ102;   Drug: LEE011;   Drug: BYL719
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Thyroid Cancer;   Thyroid Nodule;   Thyroid Neoplasms;   Thyroid Goitre;   Thyroid Diseases;   Parathyroid Diseases;   Parathyroid Adenoma;   Parathyroid Hyperplasia
    Interventions:   Drug: Acetaminophen 500Mg Cap;   Drug: Tylenol #3 Oral Tablet;   Drug: Tramadol
    Sponsor:   Minerva Romero Arenas, MD, MPH
    Recruiting

  • Conditions:   HER-2 Positive Breast Cancer;   Estrogen Receptor Positive Breast Cancer
    Interventions:   Drug: palbociclib;   Drug: trastuzumab;   Drug: pertuzumab;   Drug: letrozole;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant
    Sponsors:   Alliance Foundation Trials, LLC.;   Pfizer;   German Breast Group;   Fondazione Michelangelo;   PrECOG, LLC.;   Breast Cancer Trials, Australia and New Zealand;   Syneos Health;   SOLTI Breast Cancer Research Group;   UNICANCER
    Recruiting

  • Condition:   Metastatic Breast Cancer
    Interventions:   Drug: LY3295668 Erbumine;   Drug: Endocrine therapy;   Drug: Midazolam
    Sponsor:   Eli Lilly and Company
    Recruiting

  • Conditions:   Hyperparathyroidism;   Hypocalcemia;   Parathyroid Neoplasm;   Multiple Endocrine Neoplasia;   MEN1
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Neoplasms;   Breast Neoplasms
    Interventions:   Drug: Xentuzumab;   Drug: Abemaciclib;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Fulvestrant
    Sponsor:   Boehringer Ingelheim
    Recruiting

  • Conditions:   Hematological Malignancies;   Chronic Hypoxemic Respiratory Failure;   Blood And Marrow Transplantation;   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    Interventions:   Other: Non-Invasive Positive Pressure Ventilation (NIPPV);   Other: High Flow Nasal Cannula Oxygen Therapy
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Medullary Thyroid Carcer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Neoplasm of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasm of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Melanoma and Other Malignant Neoplasms of Skin
    Intervention:   Drug: Gemcitabine
    Sponsors:   M.D. Anderson Cancer Center;   James B. and Lois R. Archer Charitable Foundation;   Gateway for Cancer Research
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Drug: Regorafenib
    Sponsors:   Dana-Farber Cancer Institute;   Bayer
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Drug: Thyrogen;   Radiation: I-131;   Radiation: I-124
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Genetic: •Referral to Genetic Counselor, if indicated
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting

  • Condition:   Metastatic Thyroid Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Sirolimus
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Procedure: PET Imaging;   Other: 18F-tetrafluoroborate (18F-TFB)
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Diagnostic Test: Cerenkov luminescence imaging.
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract
    Interventions:   Drug: Pembrolizumab;   Biological: Clostridium Novyi-NT;   Drug: Doxycycline
    Sponsors:   M.D. Anderson Cancer Center;   BioMed Valley Discoveries, Inc;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Differentiated Thyroid Cancer
    Intervention:   Drug: rhTSH
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group - NORD;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Gastric Neoplasms;   Pancreatic Neoplasms;   Small Intestinal Neoplasms;   Colorectal Neoplasms
    Intervention:   Diagnostic Test: BRAHMS CgA II KRYPTOR
    Sponsor:   Brahms AG
    Recruiting

  • Condition:   Adrenal Gland Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Procedure: Thyroid lobectomy;   Procedure: Total thyroidectomy with CCND
    Sponsor:   University of Pittsburgh
    Recruiting

  • Conditions:   Pancreatic Cancer;   Neoplasm
    Intervention:  
    Sponsor:   Columbia University
    Recruiting

  • Conditions:   RET-altered Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   RET-altered Papillary Thyroid Cancer;   RET-altered Colon Cancer;   RET-altered Solid Tumors;   Lung Neoplasm;   Carcinoma, Non-Small-Cell Lung;   Thyroid Diseases;   Thyroid Neoplasm;   Thyroid Cancer, Papillary;   Carcinoma, Neuroendocrine;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases;   Respiratory Tract Disease;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Endocrine System Diseases;   Endocrine Gland Neoplasm;   Head and Neck Neoplasms;   Adenocarcinoma, Papillary;   Adenocarcinoma;   Carcinoma;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Neuroendocrine Tumors;   Neuroectodermal Tumors;   Neoplasms, Germ Cell and Embryonal;   Neoplasms, Nerve Tissue;   Colonic Neoplasms;   Colorectal Neoplasms;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasm;   Digestive System Disease;   Gastrointestinal Disease;   Colonic Diseases;   Intestinal Disease
    Intervention:   Drug: pralsetinib (BLU-667)
    Sponsor:   Blueprint Medicines Corporation
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Drug: Nivolumab;   Biological: NeoVax;   Procedure: Core Needle Biopsy
    Sponsors:   Dana-Farber Cancer Institute;   United States Department of Defense
    Not yet recruiting

  • Condition:   Diabetes
    Intervention:   Behavioral: Diabetes Coping Skills Training (DCST)
    Sponsor:   Duke University
    Recruiting

  • Condition:   Cancer, Thyroid
    Interventions:   Diagnostic Test: Ultrasound;   Diagnostic Test: Shear wave elasticity imaging;   Diagnostic Test: Multi-angle compound shear wave elasticity imaging
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Anaplastic Thyroid Cancer;   Thyroid Cancer
    Intervention:   Drug: MLN0128
    Sponsors:   Dana-Farber Cancer Institute;   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Pancreas Cancer
    Intervention:   Other: Supportive Oncology Care at Home
    Sponsors:   Massachusetts General Hospital;   Stand Up To Cancer
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:  
    Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreas Cancer
    Intervention:   Radiation: IORT
    Sponsors:   Massachusetts General Hospital;   IntraOp/Mobetron
    Recruiting

  • Condition:   Thyroid Gland Carcinoma
    Interventions:   Drug: Gallium Ga 68-labeled PSMA-11;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography (PET)
    Sponsor:   University of California, San Francisco
    Recruiting

  • Condition:   Thyroid
    Interventions:   Drug: Metformin Hydrochloride;   Other: Radioactive Iodine;   Other: Placebo
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:   Drug: Fostamatinib and Paclitaxel
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Rigel Pharmaceuticals;   Allegheny Health Network
    Recruiting

  • Conditions:   Invasive Cancer;   Sarcoma;   Hematologic Cancer
    Intervention:  
    Sponsors:   M.D. Anderson Cancer Center;   The Once Upon a Time Foundation
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:  
    Sponsor:   New Mexico Cancer Care Alliance
    Recruiting

  • Condition:   Thyroid
    Intervention:  
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Hope Biosciences Allogeneic, First Blood Relative Adipose-Derived Mesenchymal Stem Cells
    Sponsor:   Hope Biosciences
    Available

  • Condition:   Ovarian Cancer
    Interventions:   Drug: Enoxaparin;   Drug: Enoxaparin + Rosuvastatin;   Other: Thromboprophylaxis
    Sponsors:   Beth Israel Deaconess Medical Center;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:  
    Sponsor:   University of Washington
    Recruiting

  • Conditions:   Pancreas Cancer;   Cancer
    Intervention:   Device: CivaSheet
    Sponsor:   CivaTech Oncology
    Recruiting

  • Conditions:   Microsatellite Stable Colorectal Cancer;   Pancreatic Cancer;   MSI High Colorectal Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Radiation: Radiation Therapy
    Sponsors:   Massachusetts General Hospital;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Ficlatuzumab
    Sponsors:   Dana-Farber Cancer Institute;   AVEO Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Non-Medullary Thyroid Cancer
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Behavioral: Diet Only;   Behavioral: Diet + Exercise
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Lidocaine Hydrochloride;   Drug: Saline Solution for Injection
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Drug: VS-6063;   Drug: Paclitaxel;   Drug: Carboplatin
    Sponsors:   Michael McHale;   Verastem, Inc.;   Nine Girls Ask
    Recruiting

  • Condition:   Pancreas Cancer
    Interventions:   Drug: Pembrolizumab;   Drug: Azacitidine
    Sponsor:   Rachael A Safyan, MD
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Other: Fitness Tracker;   Other: Social Incentive (Way to Health)
    Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Biological: TT vaccine booster
    Sponsors:   Albert Einstein College of Medicine;   Pancreatic Cancer Action Network
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Talimogene laherparepvec
    Sponsors:   Yvonne Saenger;   Amgen
    Recruiting

  • Condition:   Unresectable Pancreatic Cancer
    Intervention:   Device: NanoKnife IRE System
    Sponsor:   University of Maryland, College Park
    Recruiting

  • Condition:   Testicular Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Cancer of the Pancreas
    Intervention:   Biological: huCART-meso cells
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Pancreatic Cancer;   Resectable Pancreatic Cancer
    Interventions:   Drug: Pimonidazole;   Procedure: Surgical Resection
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Varian Medical Systems
    Not yet recruiting

  • Condition:   Ovarian Cancer
    Intervention:   Device: Drug Response Predictor® (DRP)
    Sponsors:   Oncology Venture;   Amarex Clinical Research
    Recruiting

  • Conditions:   Ovarian Cancer;   Resistant BRCA Wild-Type Ovarian Cancer
    Interventions:   Drug: Cohort 1: Dose Escalation;   Drug: Cohort 2: Dose Escalation
    Sponsor:   University of Alabama at Birmingham
    Not yet recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Procedure: Computed Tomography (CT);   Behavioral: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Warfarin
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Condition:   Pancreatic Cancer Stage IV
    Interventions:   Drug: Gemcitabine;   Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO];   Drug: Cabiralizumab
    Sponsors:   Hitendra Patel;   Stand Up To Cancer
    Not yet recruiting

  • Condition:   Pancreatic Cancer
    Intervention:  
    Sponsors:   Hoag Memorial Hospital Presbyterian;   Baylor Research Institute
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Procedure: Hyperthermic intraperitoneal chemotherapy (HIPEC);   Drug: Carboplatin
    Sponsor:   Loma Linda University
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:   Drug: PTC596
    Sponsors:   University of Oklahoma;   PTC Therapeutics
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Synthetic Human Secretin
    Sponsor:   Mayo Clinic
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: [18F]FluorThanatrace ([18F]FTT)
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: First-line Chemotherapy;   Drug: Second-line Chemotherapy;   Radiation: Chemoradiation
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel
    Sponsors:   Medical College of Wisconsin;   The Cleveland Clinic
    Recruiting

  • Condition:   Breast Cancer
    Intervention:   Behavioral: Self Affirmation
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Drug: Triciribine;   Drug: Carboplatin
    Sponsor:   Prescient Therapeutics, Ltd.
    Recruiting

  • Condition:   Cancer of Pancreas
    Intervention:   Drug: Nintedanib
    Sponsors:   University of Texas Southwestern Medical Center;   Boehringer Ingelheim;   The University of Texas Health Science Center at San Antonio;   South Plains Oncology Consortium
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Radiation: SBRT
    Sponsor:   University of California, San Diego
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Paricalcitol
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Condition:   Cancer of Pancreas
    Interventions:   Drug: BGB324;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Cisplatin
    Sponsors:   University of Texas Southwestern Medical Center;   Triligent International;   Translational Genomics Research Institute;   BerGenBio ASA
    Recruiting

  • Condition:   Ovarian Cancer Recurrent
    Interventions:   Drug: Rintatolimod;   Drug: Pembrolizumab;   Drug: Cisplatin
    Sponsors:   Robert Edwards;   Hemispherx Biopharma;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Locally Advanced Pancreatic Cancer;   Pancreatic Cancer
    Intervention:   Drug: FOLFOXA
    Sponsors:   howard safran;   Brown University;   Rhode Island Hospital
    Recruiting

  • Condition:   Cancer of Pancreas
    Interventions:   Dietary Supplement: Nutrawell Powder;   Other: Diet Only;   Dietary Supplement: OmegaRich fish oil supplement
    Sponsor:   Jonsson Comprehensive Cancer Center
    Recruiting

  • Condition:   Cancer of Pancreas
    Intervention:   Behavioral: Walking Intervention
    Sponsor:   Fox Chase Cancer Center
    Recruiting

  • Condition:   Advanced Ovarian Cancer
    Interventions:   Drug: 2X-121;   Device: 2X-121 DRP®
    Sponsors:   Oncology Venture;   Alcedis GmbH;   Amarex Clinical Research
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: GVAX;   Drug: Pembrolizumab;   Radiation: SBRT
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Pancreas Cancer
    Intervention:   Procedure: Muscle Tissue Biopsy Sample
    Sponsors:   University of Florida;   The V Foundation for Cancer Research;   National Institutes of Health (NIH)
    Recruiting

  • Conditions:   Advanced Pancreatic Cancer;   Advanced Solid Tumor
    Interventions:   Drug: Metformin;   Drug: Simvastatin;   Drug: Digoxin
    Sponsor:   John Nemunaitis, MD
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Biological: GVAX pancreatic cancer;   Drug: Nivolumab;   Drug: Urelumab
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI);   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Cancer Pancreas;   Pain Syndrome;   Cancer Related Pain
    Intervention:   Device: Scrambler Therapy Device
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Ho-Chiang Foundation
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Device: Back-loaded Needle (Device);   Device: Preloaded Needle (Device)
    Sponsors:   University of Colorado, Denver;   Cook Group Incorporated
    Recruiting

  • Condition:   Locally Advanced Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Radiation: Hypofractionated Ablative Proton Therapy
    Sponsor:   University of Maryland, Baltimore
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreatic Neoplasms
    Intervention:   Diagnostic Test: MRI/MRCP
    Sponsors:   Western Connecticut Health Network;   Yale University
    Recruiting

  • Conditions:   Locally Advanced Pancreatic Cancer;   Borderline Pancreatic Inoperable Cancer;   Pancreatic Cancer
    Interventions:   Drug: Folfirinox;   Drug: Gemcitabine nab-Paclitaxel
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Biological: LOAd703;   Drug: Gemcitabine;   Drug: nab-paclitaxel
    Sponsor:   Lokon Pharma AB
    Recruiting

  • Condition:   Unresectable Pancreatic Cancer
    Interventions:   Radiation: Radiation Therapy;   Drug: Concurrent chemotherapy (Gemcitabine, Capecitabine)
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Condition:   Anaplastic Thyroid Cancer
    Interventions:   Drug: Trametinib;   Drug: Paclitaxel
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Novartis
    Recruiting

  • Condition:   Debulking Surgery for Ovarian Cancer
    Intervention:   Dietary Supplement: nsure Surgery Immunonutrition Shake supplements
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Anaplastic Thyroid Cancer
    Intervention:   Drug: Pembrolizumab
    Sponsors:   University of Texas Southwestern Medical Center;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer
    Interventions:   Procedure: HIPEC;   Drug: Carboplatin;   Drug: Paclitaxel
    Sponsors:   Andrea Jewell;   University of Kansas Medical Center
    Recruiting

  • Conditions:   Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy;   Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy
    Interventions:   Radiation: Radiotherapy;   Drug: Gemcitabine 1000 mg;   Drug: nab-paclitaxel 125 mg
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreas Cancer;   Cancer of the Pancreas
    Interventions:   Drug: 5-FU;   Drug: Leucovorin;   Drug: Liposomal Irinotecan;   Drug: Paricalcitol;   Procedure: Serum and plasma blood samples;   Procedure: Tumor biopsy
    Sponsors:   Washington University School of Medicine;   Ipsen
    Recruiting

  • Condition:   Pancreatic Neoplasms
    Intervention:   Diagnostic Test: MRI/MRCP
    Sponsor:   Western Connecticut Health Network
    Recruiting

  • Conditions:   Stage I Papillary Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Papillary Thyroid Cancer
    Interventions:   Procedure: Thyroidectomy;   Procedure: Central lymph node dissection;   Other: Quality-of-life assessment
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI);   National Institutes of Health (NIH)
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: CPI 613
    Sponsor:   Jeffrey Hardacre
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Nivolumab + Cabiralizumab;   Radiation: Stereotactic Body Radiotherapy (SBRT)
    Sponsor:   NYU Langone Health
    Recruiting

  • Conditions:   Ovarian Cancer;   Ovarian Neoplasms
    Interventions:   Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
    Sponsors:   Duke University;   Johns Hopkins University;   Genentech, Inc.
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Behavioral: Group Session;   Behavioral: Telephone Coaching Session;   Behavioral: Webinar
    Sponsors:   Dana-Farber Cancer Institute;   Patty Brisben Foundation For Women's Sexual Health
    Recruiting

  • Conditions:   Tumor, Solid;   Pancreatic Cancer
    Interventions:   Drug: Ulixertinib;   Drug: Palbociclib
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   BioMed Valley Discoveries, Inc;   Pfizer
    Recruiting

  • Conditions:   Other Disorders of Glucose Regulation and Pancreatic Internal Secretion;   Pancreatic Cancer
    Interventions:   Behavioral: Questionnaires;   Behavioral: Nutritional Questionnaire and Nutritional Counseling;   Other: Booklet;   Behavioral: Aerobic Exercise and Strength Training Exercises;   Behavioral: Phone Calls;   Behavioral: Physical Assessments
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: ARQ-761;   Drug: Gemcitabine;   Drug: nab-paclitaxel
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Condition:   Pancreas Cancer
    Interventions:   Radiation: 10 Gy Low-KV IORT;   Radiation: 15 Gy Low-KV IORT;   Radiation: 20 GY Low-KV IORT
    Sponsor:   Loyola University
    Recruiting

  • Conditions:   Malignant Neoplasm of Ovary;   Malignant Neoplasm of Fallopian Tube;   Malignant Neoplasm of Peritoneum
    Intervention:   Procedure: Diagnostic laparoscopy
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Condition:   Pancreatic Cancer, ATM, BRCA, Hereditary Cancer
    Intervention:  
    Sponsors:   Johns Hopkins University;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreas Cancer;   Melanoma
    Intervention:  
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Surgery
    Intervention:  
    Sponsor:   Duke University
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
    Interventions:   Drug: MOv19-BBz CAR T cells;   Device: Alpha Folate Receptor expression test
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
    Intervention:   Biological: Autologous Monocytes + ACTIMMUNE + SYLATRON
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Neoplasm
    Interventions:   Drug: Ascorbate;   Drug: Gemcitabine;   Radiation: radiation therapy
    Sponsors:   Joseph J. Cullen;   Holden Comprehensive Cancer Center
    Not yet recruiting

  • Conditions:   Cervical Cancer;   Endometrial Cancer;   Ovarian Epithelial Cancer
    Intervention:   Drug: Fluciclovine F18
    Sponsors:   Bital Savir-Baruch;   Blue Earth Diagnostics
    Recruiting

  • Conditions:   Pancreas Cancer;   Pancreatic Cancer;   Cancer of the Pancreas
    Interventions:   Biological: Neoantigen Peptide Vaccine;   Drug: Poly ICLC;   Procedure: Blood for immune monitoring
    Sponsors:   Washington University School of Medicine;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Viragh Foundation
    Recruiting

  • Conditions:   FIGO Stage III and IV Ovarian Cancer;   FIGO Stage III and IV Fallopian Tube Cancer;   FIGO Stage III Primary Peritoneal Cancer
    Interventions:   Biological: ALT-803 Subcutaneous;   Biological: ALT-803 Intraperitoneal
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Pancreas Cancer;   Pancreas Cyst
    Intervention:   Other: Lateral Flow Assay (LFA)
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreatic Neoplasms
    Intervention:   Procedure: Endoscopic ultrasound guided fine needle biopsy
    Sponsor:   Texas Tech University Health Sciences Center, El Paso
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreas Cancer;   Cancer of the Pancreas
    Interventions:   Biological: Personalized neoantigen DNA vaccine;   Device: TDS-IM Electrode Array System;   Procedure: Peripheral blood draws
    Sponsors:   Washington University School of Medicine;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Behavioral: Nutritional Counseling;   Behavioral: Standard Exercise;   Behavioral: Enhanced Exercise
    Sponsor:   University of Oklahoma
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
    Intervention:  
    Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   United States Department of Defense
    Recruiting

  • Condition:   Ovarian Neoplasms
    Intervention:   Procedure: Abnormal Ovarian Ultrasound
    Sponsors:   Frederick R. Ueland, M.D.;   Lucille P. Markey Cancer Center at University of Kentucky
    Recruiting

  • Conditions:   Diabetes Mellitus;   Cancer
    Interventions:   Drug: Oral Glucose Tolerance Test (OGTT);   Drug: 2 OGTTs with and without GLP-1;   Drug: Hyperglycemic clamp procedure
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
    Intervention:   Drug: Cisplatin
    Sponsors:   Northwell Health;   Katie Oppo Foundation
    Recruiting

  • Conditions:   Ovarian Cancer;   Peritoneal Carcinomatosis;   Fallopian Tube Cancer
    Intervention:   Biological: GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
    Sponsor:   Genelux Corporation
    Recruiting

  • Conditions:   Malignant Neoplasms of Female Genital Organs;   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Intervention:   Drug: Bevacizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Thyroid Cancer;   Thyroid Nodule
    Intervention:   Other: No intervention: observational only
    Sponsor:   University of Virginia
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Niraparib
    Sponsors:   Dana-Farber Cancer Institute;   Tesaro, Inc.
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:   Biological: DC vaccination
    Sponsor:   Loyola University
    Recruiting

  • Conditions:   Metastatic Pancreatic Adenocarcinoma;   Stage IV Pancreatic Cancer AJCC v8
    Interventions:   Biological: Pegylated Recombinant Human Hyaluronidase PH20;   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: GVAX Pancreas Vaccine;   Drug: CRS-207
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Aduro Biotech, Inc.;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer
    Interventions:   Drug: AVB-S6-500;   Drug: Paclitaxel;   Drug: Carboplatin;   Procedure: Tissue from Diagnostic Laparoscopy;   Procedure: Tissue from Core biopsy;   Procedure: Interval Debulking;   Procedure: Peripheral blood;   Procedure: Ascites collection
    Sponsors:   Washington University School of Medicine;   Aravive, Inc.
    Not yet recruiting

  • Conditions:   Pancreatic Neoplasms;   Neoplasm Metastasis;   Liver Metastases
    Intervention:   Procedure: Hepatic Resection or Ablation with Pancreaticoduodenectomy
    Sponsor:   Duke University
    Recruiting

  • Condition:   Pituitary Tumor
    Intervention:  
    Sponsor:   Cedars-Sinai Medical Center
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Anemia;   Iron Deficiency Anemia
    Intervention:   Other: Iron Sucrose
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Malignant Ovarian Neoplasm;   Ovarian Carcinoma
    Interventions:   Radiation: Dynamic Enhanced CT;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Chronic Pancreatitis;   Diabetes Mellitus Type 3c
    Intervention:   Other: Data Management and Monitoring
    Sponsors:   M.D. Anderson Cancer Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Pancreatic Carcinoma;   Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type
    Interventions:   Procedure: Optical Coherence Tomography;   Procedure: Therapeutic Conventional Surgery;   Diagnostic Test: Laboratory Evaluation
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Pancreas Cancer;   Prostate Cancer;   Hereditary Cancer;   Genetic Predisposition to Disease
    Intervention:   Behavioral: Genetic testing for hereditary predisposition
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Pancreatic Cancer;   Cachexia;   Weight Loss
    Intervention:   Drug: Xilonix plus Onivyde and 5FU
    Sponsors:   Andrew Hendifar, MD;   Ipsen;   XBiotech, Inc.
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Biological: multiTAA specific T cells
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System;   Pancreatic Cancer Action Network;   The V Foundation for Cancer Research;   Harris County Hospital District
    Recruiting

  • Conditions:   Pancreas Adenocarcinoma;   Resectable Pancreatic Cancer
    Interventions:   Drug: Gemcitabine 1000 mg;   Drug: nab-paclitaxel;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   Loma Linda University
    Recruiting

  • Condition:   Familial Pancreatic Cancer
    Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review;   Other: survey administration
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ovarian Cancer;   Breast Cancer
    Intervention:  
    Sponsors:   NYU Langone Health;   Lynne Cohen Foundation for Ovarian Cancer Research
    Recruiting

  • Conditions:   Pancreatic Insufficiency;   Pancreatic Cancer;   Pancreatic Enzyme Abnormality
    Interventions:   Drug: Pancrelipase;   Drug: Placebo Oral Capsule
    Sponsors:   Massimo Raimondo, M.D.;   Digestive Care, Inc.
    Recruiting

  • Condition:   Recurrent Ovarian Cancer
    Interventions:   Diagnostic Test: ChemoID assay;   Drug: Chemotherapy
    Sponsor:   Cordgenics, LLC
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Device: prophylactic endoscopic ultrasound
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Conditions:   Thyroid Nodule;   Thyroid Cancer
    Intervention:   Other: Thyroid Decision Aid
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Thyroid Cancer;   Thyroid Cancer, Medullary;   Differentiated Thyroid Cancer;   Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Poorly Differentiated Thyroid Gland Carcinoma
    Interventions:   Drug: Lenvatinib;   Drug: Sorafenib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:   Drug: VAL-083, Dianhydrogalactitol
    Sponsor:   DelMar Pharmaceuticals, Inc.
    Not yet recruiting

  • Condition:   Metastatic Pancreatic Cancer
    Intervention:   Drug: FOLFOXA
    Sponsors:   howard safran;   Brown University;   Lifespan;   SouthCoast Medical Group;   Memorial hospital
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Ovarian Diseases;   Fallopian Tube Diseases;   Peritoneal Diseases
    Interventions:   Procedure: Baseline Biopsy;   Procedure: Tissue Collection;   Procedure: Blood Draws
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   The V Foundation for Cancer Research;   Kay Yow Cancer Fund
    Recruiting

  • Condition:   Ovarian Epithelial Cancer
    Intervention:   Drug: SPL-108
    Sponsor:   Splash Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Chronic Pancreatitis;   Diabetes;   Pancreatic Cancer
    Intervention:   Other: Data Management and Monitoring
    Sponsors:   M.D. Anderson Cancer Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Cancer Institute (NCI);   National Institutes of Health (NIH)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Nivolumab;   Drug: GVAX Pancreas Vaccine;   Radiation: Stereotactic Body Radiation (SBRT)
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
    Intervention:   Drug: Olaparib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   AstraZeneca
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:  
    Sponsor:   Columbia University
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Device: TraceIT Tissue Spacer implantation
    Sponsor:   Boston Scientific Corporation
    Recruiting

  • Condition:   Stage III Pancreatic Cancer
    Interventions:   Drug: SOC;   Device: NanoKnife System
    Sponsor:   Angiodynamics, Inc.
    Recruiting

  • Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Solid Neoplasm;   Stage IV Pancreatic Cancer
    Interventions:   Drug: Disulfiram;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pituitary Adenoma;   Pituitary Tumor
    Interventions:   Procedure: Surgical intervention for CNFA;   Radiation: Radiotherapy for CNFA
    Sponsors:   Columbia University;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  • Conditions:   Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer;   HER2-Negative Breast Cancer;   Metastatic Epithelial Ovarian Cancer
    Interventions:   Drug: Ribociclib;   Drug: PDR001;   Drug: Fulvestrant
    Sponsors:   Dana-Farber Cancer Institute;   Novartis
    Recruiting

  • Condition:   Metastatic Pancreatic Cancer
    Interventions:   Genetic: SGT-53;   Drug: nab-paclitaxel;   Drug: Gemcitabine
    Sponsor:   SynerGene Therapeutics, Inc.
    Recruiting

  • Conditions:   Pancreatic Ductal Adenocarcinoma (PDAC);   Cancer of Pancreas;   Pancreatic Cancer, Adult;   Pancreas Adenocarcinoma;   Pancreatic Neoplasms;   Pancreatic Cancer Non-resectable;   Pancreatic Cancer Resectable
    Interventions:   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: Irinotecan Hydrochloride;   Drug: 5-FU
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Colon Cancer;   Pancreatic Cancer;   Cholangiocarcinoma;   Mestatic Colon Carcinoma;   Liver Metastasis
    Interventions:   Drug: MVT-5873;   Procedure: pancreatectomy or hepatectomy
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Metastatic;   Melanoma;   Non Small Cell Lung Cancer (NSCLC);   Breast Cancer;   Pancreatic Cancer
    Interventions:   Radiation: Radiotherapy;   Drug: MEDI4736;   Drug: Tremelimumab
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Progressive Disease;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IIIA Fallopian Tube Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Primary Peritoneal Cancer AJCC v8;   Stage IIIA1 Fallopian Tube Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Fallopian Tube Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Fallopian Tube Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Primary Peritoneal Cancer AJCC v8;   Stage IIIC Fallopian Tube Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8
    Intervention:   Biological: PRGN-3005 UltraCAR-T cells
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Precigen, Inc
    Recruiting

  • Conditions:   Ovarian Cancer Stage III;   Ovarian Cancer Stage IV;   Breast Cancer Stage IV;   Cervical Cancer Stage IIIB;   Cervical Cancer Stage IVA;   Cervical Cancer Stage IVB;   Endometrial Cancer Stage III;   Endometrial Cancer Stage IV;   Vulvar Cancer, Stage III;   Vulvar Cancer, Stage IV;   Vaginal Cancer Stage III;   Vaginal Cancer Stage IVA;   Vaginal Cancer Stage IVB
    Intervention:   Behavioral: Strong Together serious game
    Sponsor:   University of Pittsburgh
    Recruiting

  • Condition:   Pancreas Cancer
    Intervention:   Device: Ultrasound
    Sponsor:   Allen Li
    Recruiting

  • Condition:   Gastroenteropancreatic Neuroendocrine Tumors
    Interventions:   Drug: Somatuline Depot;   Drug: Keytruda
    Sponsors:   Duke University;   Merck Sharp & Dohme Corp.;   Ipsen
    Recruiting

  • Condition:   Adnexal Mass
    Intervention:  
    Sponsor:   Natera, Inc.
    Recruiting

  • Conditions:   KRAS NP_004976.2:p.G12D;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Stage IV Pancreatic Cancer AJCC v8
    Intervention:   Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Adnexal Masses;   Ovarian Cysts;   Ovarian Tumors
    Intervention:  
    Sponsor:   KU Leuven
    Recruiting

  • Conditions:   Heptocellular Carcinoma;   Heptocellular Cancer;   Metastatic Pancreatic Cancer;   Metastatic Colorectal Cancer;   Liver Metastasis
    Interventions:   Drug: nivolumab;   Drug: tadalafil;   Drug: oral vancomycin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hurthle Cell Thyroid Cancer;   Tall Cell Variant Thyroid Cancer;   Follicular Thyroid Cancer;   Thyroid Cancer;   Papillary Thyroid Cancer
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Pancrelipase
    Sponsors:   Dana-Farber Cancer Institute;   Allergan
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Biological: FATE-NK100;   Drug: Interleukin-2
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Cancer of Ovary;   Cancer of the Ovary;   Neoplasms, Ovarian;   Ovarian Cancer;   Ovary Cancer;   Ovary Neoplasms
    Interventions:   Biological: Cisplatin + celecoxib + DC vaccine;   Biological: Cisplatin + CKM + Celecoxib + DC Vaccine
    Sponsors:   Roswell Park Cancer Institute;   Hemispherx Biopharma;   National Cancer Institute (NCI);   University of Pittsburgh
    Recruiting

  • Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Pancreatic Cancer;   Stereotactic Body Radiation Therapy
    Interventions:   Drug: GC4419;   Drug: Placebo;   Radiation: Stereotactic Radiation Therapy (SBRT)
    Sponsors:   Galera Therapeutics, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Pancreatic Neoplasms;   Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms;   Adenocarcinoma
    Interventions:   Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: Pharmacological ascorbate
    Sponsors:   Joseph J. Cullen;   National Institutes of Health (NIH);   National Cancer Institute (NCI);   Holden Comprehensive Cancer Center;   McGuff Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Cancer Survivor;   Caregiver;   Family Member;   Health Care Provider;   Thyroid Gland Medullary Carcinoma
    Interventions:   Other: Decision Aid;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Peritoneal Cancer;   Ovarian Cancer;   Fallopian Tube Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Nivolumab;   Drug: Rucaparib
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Candidates for Hereditary Pancreatic Cancer Testing
    Interventions:   Other: Doxy.me genetic education +/- Color Genomics genetic education;   Other: Color Genomics genetic education
    Sponsors:   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   Johns Hopkins University;   University of California, San Diego;   Mayo Clinic;   Weill Cornell Medicine;   Stand Up To Cancer;   Lustgarten Foundation
    Recruiting

  • Conditions:   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma;   Ovarian Carcinoma;   Fallopian Tube Carcinoma
    Interventions:   Procedure: Cytoreductive Surgery (CRS);   Drug: Adjuvant Chemotherapy;   Other: Questionnaire;   Procedure: Hyperthermic intraperitoneal chemotherapy;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Cisplatin
    Sponsor:   Mercy Medical Center
    Recruiting

  • Conditions:   Stage II Fallopian Tube Cancer AJCC v8;   Stage II Ovarian Cancer AJCC v8;   Stage II Primary Peritoneal Cancer AJCC v8;   Stage IIA Fallopian Tube Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIA Primary Peritoneal Cancer AJCC v8;   Stage IIB Fallopian Tube Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage IIB Primary Peritoneal Cancer AJCC v8;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IIIA Fallopian Tube Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Primary Peritoneal Cancer AJCC v8;   Stage IIIA1 Fallopian Tube Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Fallopian Tube Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Fallopian Tube Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Primary Peritoneal Cancer AJCC v8;   Stage IIIC Fallopian Tube Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8
    Interventions:   Biological: Alpha-type-1 Polarized Dendritic Cells;   Biological: Autologous Natural Killer Cell-like CTLs
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Stage III Fallopian Tube Cancer AJCC v7;   Stage III Ovarian Cancer AJCC v6 and v7;   Stage III Primary Peritoneal Cancer AJCC v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Pancreatic Carcinoma;   Stage II Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unresectable Pancreatic Carcinoma
    Interventions:   Drug: Hydroxychloroquine;   Drug: Trametinib
    Sponsors:   University of Utah;   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Pancreatic Adenocarcinoma;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer;   Recurrent Pancreatic Carcinoma
    Interventions:   Drug: Gemcitabine;   Drug: Sorafenib;   Drug: Vorinostat;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: RosetteSep;   Other: DEPfff
    Sponsors:   Virginia Commonwealth University;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRCA-Mutated Ovarian Carcinoma;   BRIP1 Gene Mutation;   MSH2 A636P;   MLH1 Gene Mutation;   MSH6 Gene Mutation;   PMS2 Gene Mutation;   EPCAM;   RAD51C Gene Mutation
    Intervention:   Other: CASCADE genetic screening
    Sponsor:   NYU Langone Health
    Recruiting

  • Conditions:   Islet Cell Tumor;   Pancreatic Cancer;   Pancreatic Disease
    Interventions:   Other: medical chart review;   Other: survey administration;   Other: biospecimen collection
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Kidney Cancer;   Multiple Myeloma;   Ovary Cancer;   Prostate Cancer
    Interventions:   Behavioral: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health;   Other: Diet-Exercise;   Other: Exercise-Diet;   Other: Wait-list Control- Combined Diet and Exercise
    Sponsors:   University of Alabama at Birmingham;   University of Tennessee Health Science Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Drug: Ixabepilone;   Drug: Bevacizumab
    Sponsors:   Yale University;   R-Pharm-US, LLC
    Recruiting

  • Conditions:   Pancreatic Adenocarcinoma;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8
    Interventions:   Biological: Pembrolizumab;   Biological: Wild-type Reovirus
    Sponsors:   Northwestern University;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:   Other: Bolster
    Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma;   Stage I Ovarian Cancer;   Stage IA Ovarian Cancer;   Stage IB Ovarian Cancer;   Stage IC Ovarian Cancer;   Stage II Ovarian Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Ovarian Cancer;   Stage III Ovarian Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Ovarian Cancer
    Interventions:   Procedure: Diagnostic Microscopy;   Drug: Fluorescein Sodium Injection;   Other: Laboratory Biomarker Analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Adenocarcinoma;   Liver Metastases
    Intervention:   Combination Product: FUDR via HAI pump
    Sponsor:   Spectrum Health Hospitals
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:  
    Sponsors:   Southern Illinois University;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Adenocarcinoma
    Interventions:   Drug: Gemcitabine;   Drug: nab paclitaxel;   Drug: Onivyde;   Drug: Leucovorin;   Drug: 5-fu
    Sponsor:   Benaroya Research Institute
    Recruiting

  • Conditions:   Endocrine Disease;   Infertility;   Leiomyoma;   Endometriosis;   Fibroids
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Fallopian Tube Carcinoma;   Peritoneal Carcinoma;   Epithelial Ovarian Cancer
    Interventions:   Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin
    Sponsors:   Marilyn Huang;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Erdafitinib;   Drug: Palbociclib;   Drug: Fulvestrant
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cyst;   Pancreas Disease
    Intervention:   Diagnostic Test: Bio-Specimen Collection
    Sponsors:   Stanford University;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Breast Neoplasm;   Malignant Colorectal Neoplasm;   Malignant Pancreatic Neoplasm;   Malignant Solid Neoplasm
    Interventions:   Procedure: Computed Tomography;   Radiation: Fluorine F 18-fluoroazomycin Arabinoside;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Neoplasms
    Intervention:   Device: EUS with Fiducial
    Sponsor:   University of Southern California
    Recruiting

  • Conditions:   Recurrent Gynecological Cancer;   Metastatic Cervical Cancer;   Metastatic Ovarian Cancer;   Metastatic Vaginal Cancer;   Metastatic Vulvar Cancer;   Metastatic Endometrial Cancer;   Recurrent Cervical Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Recurrent Endometrial Cancer
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Radiation: Radiation Therapy
    Sponsors:   Dana-Farber Cancer Institute;   AstraZeneca
    Recruiting

  • Conditions:   Colorectal Neoplasms;   Gastric Neoplasms;   Cholangiocarcinoma;   Bile Duct Cancer;   Pancreas Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cysts;   Intraductal Papillary Mucinous Neoplasm;   Pancreatic Mucinous-Cystic Neoplasm;   Cystic, Mucinous and/or Serous Neoplasm;   Solid Pseudopapillary Tumour of the Pancreas
    Intervention:  
    Sponsor:   Johns Hopkins University
    Recruiting

  • Conditions:   Solid Tumor, Adult;   Metastatic Nonsmall Cell Lung Cancer;   Anatomic Stage IV Breast Cancer AJCC v8;   Metastatic Cervical Carcinoma;   Metastatic Ovarian Carcinoma;   Malignant Uterine Neoplasm;   Vulvar Cancer;   Invasive Breast Cancer;   Metastatic Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Vulvar Carcinoma;   Stage IV Cervical Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Vulvar Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Vulvar Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Vulvar Cancer AJCC v8;   Vulva Squamous Cell Carcinoma
    Interventions:   Other: Blood draws;   Other: QLQ-CIPN20 Survey;   Other: PR-CTCAE Survey
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Health Care Provider;   Malignant Brain Neoplasm;   Malignant Genitourinary System Neoplasm;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Pancreatic Cancer;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Pancreatic Cancer;   Stage IVB Prostate Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
    Interventions:   Procedure: Biospecimen Collection;   Other: Genetic Testing;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non Small Cell Lung Cancer;   Ovarian Cancer;   RET Gene Mutation;   BRAF Gene Mutation
    Intervention:   Drug: RXDX-105
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Resectable Pancreatic Cancer;   Unresectable Pancreatic Cancer;   Pancreatic Adenocarcinoma;   Neoadjuvant Pancreatic Cancer
    Intervention:   Drug: Paclitaxel Protein Bound (Abraxane)
    Sponsor:   HonorHealth Research Institute
    Recruiting

  • Conditions:   Recurrent Cervical Carcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Vaginal Carcinoma;   Stage IV Cervical Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IV Vaginal Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8;   Stage IVB Vaginal Cancer AJCC v8
    Interventions:   Procedure: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Talazoparib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Locally Advanced Pancreatic Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma
    Intervention:   Drug: EGFR BATs after standard of care chemo
    Sponsor:   University of Virginia
    Recruiting

  • Conditions:   Pleuropulmonary Blastoma;   Cystic Nephroma;   Ovarian Sertoli-Leydig Cell Tumors;   Ocular Medulloepithelioma;   Nasal Chondromesenchymal Hamartoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Healthy Subject;   Pancreatic Carcinoma
    Interventions:   Diagnostic Test: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Diagnostic Test: PET/MRI scan;   Drug: [18F]FP-R01-MG-F2
    Sponsors:   Sanjiv Sam Gambhir;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Peritoneal Neoplasm;   Malignant Retroperitoneal Neoplasm;   Peritoneal Carcinomatosis;   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Cervical Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacokinetic Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRCA-Mutated Ovarian Carcinoma;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IIIA Fallopian Tube Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Primary Peritoneal Cancer AJCC v8;   Stage IIIA1 Fallopian Tube Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Fallopian Tube Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Fallopian Tube Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Primary Peritoneal Cancer AJCC v8;   Stage IIIC Fallopian Tube Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8
    Interventions:   Drug: Chemotherapy;   Drug: Olaparib;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine;   Extrapulmonary Small Cell Cancer
    Interventions:   Drug: Topotecan;   Drug: VX-970 (M6620)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Radiation: Stereotactic MRI-guided On-table Adaptive Radiation Therapy
    Sponsor:   Viewray Inc.
    Recruiting

  • Condition:   Metastatic Pancreatic Adenocarcinoma
    Interventions:   Drug: Epacadostat;   Drug: Pembrolizumab;   Biological: CRS-207;   Drug: CY;   Biological: GVAX
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Malignant Ovarian Epithelial Tumor;   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Drug: Akt/ERK Inhibitor ONC201;   Drug: Paclitaxel;   Other: Questionnaire Administration
    Sponsor:   Ira Winer
    Not yet recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Adenosarcoma;   Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Malignant Ovarian Brenner Tumor;   Ovarian Adenocarcinoma;   Ovarian Adenosarcoma;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma
    Interventions:   Other: Exercise Counseling;   Other: Aerobic Exercise;   Other: Physiological Support;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Best Practice
    Sponsor:   University of Washington
    Recruiting

  • Conditions:   BRAF NP_004324.2:p.V600M;   BRAF V600E Mutation Present;   Metastatic Thyroid Gland Carcinoma;   Refractory Thyroid Gland Carcinoma;   Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8;   Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8;   Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
    Interventions:   Drug: Binimetinib;   Drug: Encorafenib;   Biological: Nivolumab
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Pancreatic Mucinous-Cystic Neoplasm
    Intervention:   Drug: NanoPac®
    Sponsors:   NanOlogy, LLC;   US Biotest, Inc.
    Recruiting

  • Conditions:   Metastatic Pancreatic Adenocarcinoma;   Refractory Pancreatic Adenocarcinoma;   Stage IV Pancreatic Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Radiation: Radiation Therapy;   Drug: TLR9 Agonist SD-101
    Sponsors:   University of California, Davis;   National Cancer Institute (NCI);   Bristol-Myers Squibb;   Dynavax Technologies Corporation
    Not yet recruiting

  • Conditions:   Ovarian Cancer;   Adnexal Mass
    Interventions:   Drug: Method 1: Indocyanine green dye;   Drug: Method 2: Indocyanine green dye;   Drug: Method 3: Indocyanine green dye
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Breast Neoplasms;   Ovarian Neoplasms;   Colonic Neoplasms;   Prostatic Neoplasms;   Uterine Cervical Neoplasms;   Leukemia;   Lymphoma, Non-Hodgkin
    Intervention:  
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Pancreas Cancer
    Intervention:   Drug: Bethanechol
    Sponsor:   Columbia University
    Recruiting

  • Condition:   Pancreas Cancer
    Interventions:   Procedure: Irreversible Electroporation (IRE);   Drug: Gemcitabine;   Drug: FOLFIRINOX
    Sponsor:   University of Louisville
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreatic Ductal Adenocarcinoma
    Interventions:   Drug: Lonsurf;   Drug: Gemcitabine;   Drug: Nab-Paclitaxel
    Sponsors:   Patrick Joseph Loehrer Sr.;   Indiana University;   Taiho Oncology, Inc.
    Not yet recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   KRAS Gene Mutation;   Ovarian Carcinoma;   Refractory Malignant Solid Neoplasm;   Refractory Ovarian Carcinoma
    Interventions:   Drug: Paclitaxel;   Other: Pharmacokinetic Study;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Solid Neoplasm;   Stage III Pancreatic Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer;   Sarcoma;   Colorectal Cancer;   Head and Neck Cancer;   Cancer of Unknown Primary;   Bladder Cancer;   Ovarian Cancer
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Palbociclib
    Sponsors:   Emory University;   Pfizer
    Recruiting

  • Conditions:   Gastric Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Unresectable Esophageal Carcinoma;   Unresectable Pancreatic Carcinoma
    Intervention:   Dietary Supplement: Zinc
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Male Breast Cancer;   Recurrent Melanoma;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Hepatocellular Carcinoma
    Interventions:   Drug: propranolol hydrochloride;   Other: Correlative Studies
    Sponsor:   William Carson
    Recruiting

  • Conditions:   Ovarian Cancer;   Peritoneum Tumors
    Intervention:   Behavioral: Data Collection
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Cervical Adenosarcoma;   Cervical Adenosquamous Carcinoma;   Cervical Carcinosarcoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Mucinous Adenocarcinoma;   Endometrial Squamous Cell Carcinoma;   Endometrial Transitional Cell Carcinoma;   Endometrial Undifferentiated Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Epithelial Tumor;   Malignant Peritoneal Neoplasm;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Skin Melanoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma;   Uterine Corpus Carcinosarcoma
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRAF NP_004324.2:p.V600E;   BRAF V600K Mutation Present;   Thyroid Gland Anaplastic Carcinoma
    Interventions:   Drug: Dabrafenib;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Trametinib
    Sponsors:   Manisha Shah;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Drug: Anti-AXL Fusion Protein AVB-S6-500;   Biological: Durvalumab
    Sponsors:   M.D. Anderson Cancer Center;   Aravive, Inc.;   AstraZeneca;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Locally Advanced Unresectable Pancreatic Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Adenocarcinoma;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8
    Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Telotristat Ethyl
    Sponsors:   Emory University;   Lexicon Pharmaceuticals
    Recruiting

  • Conditions:   Colorectal Cancer;   Pancreatic Cancer;   Adenocarcinoma of Lung;   Squamous Cell Lung Cancer;   Breast Cancer;   Mucinous Carcinoma of Ovary;   Signet Ring Cell Carcinoma of Ovary
    Intervention:   Drug: NEO-201
    Sponsor:   Precision Biologics, Inc
    Recruiting

  • Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Durvalumab;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Procedure: Mesenchymal Stem Cell Transplantation;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer, Metastatic;   Cancer;   Cancer of Pancreas;   Cancer of Liver;   Cancer of Stomach;   Cancer Liver;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Cervix;   Cancer of Colon;   Cancer of Larynx;   Cancer, Lung;   Cancer, Breast;   Cancer, Advanced;   Cancer Prostate;   Cancer of Neck;   Cancer of Skin;   Neuroendocrine Tumors;   Carcinoma;   Mismatch Repair Deficiency;   BRCA Gene Rearrangement;   Non Hodgkin Lymphoma;   Leukemia;   Non Small Cell Lung Cancer;   Cholangiocarcinoma;   Glioblastoma;   Central Nervous System Tumor;   Melanoma;   Urothelial Carcinoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Testicular Cancer;   Breast Cancer
    Intervention:   Other: Clinical Trial Matching
    Sponsor:   Massive Bio, Inc.
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   HLA-DP4 Positive Cells Present;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Other: Cellular Therapy;   Drug: Melphalan
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreatic Adenocarcinoma
    Intervention:   Diagnostic Test: CTC isolocation and analysis
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Ovarian Neoplasm;   Uterine Neoplasm
    Interventions:   Other: Informational Intervention;   Other: Questionnaire Administration;   Behavioral: Telephone-Based Intervention
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Differentiated Thyroid Gland Carcinoma;   Thyroid Gland Follicular Carcinoma;   Thyroid Gland Papillary Carcinoma
    Intervention:   Drug: Lenvatinib
    Sponsors:   Emory University;   Eisai Inc.
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Adenocarcinoma Resectable;   Pancreatic Ductal Adenocarcinoma;   Pancreas Metastases
    Interventions:   Drug: Ascorbic Acid;   Drug: Paclitaxel protein-bound;   Drug: Cisplatin;   Drug: Gemcitabine
    Sponsors:   HonorHealth Research Institute;   Stand Up To Cancer;   Cancer Research UK;   Lustgarten Foundation;   Translational Genomics Research Institute;   Princeton University;   Salk Institute for Biological Studies;   Cold Spring Harbor Laboratory;   Barts Cancer Institute;   University of Arizona;   Imaging Endpoints
    Recruiting

  • Conditions:   Bone Sarcoma;   Dedifferentiated Chondrosarcoma;   Giant Cell Tumor of Bone;   Malignancy in Giant Cell Tumor of Bone;   Ovarian Carcinosarcoma;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Osteosarcoma;   Refractory Osteosarcoma;   Refractory Ovarian Carcinoma;   Soft Tissue Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Biological: Aldesleukin;   Biological: Autologous Tumor Infiltrating Lymphocytes LN-145;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Differentiated Thyroid Gland Carcinoma;   Follicular Variant Thyroid Gland Papillary Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Progressive Thyroid Carcinoma;   Refractory Thyroid Gland Carcinoma;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Follicular Carcinoma;   Thyroid Gland Hurthle Cell Carcinoma;   Thyroid Gland Papillary Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Ovarian Tumor
    Intervention:   Other: ADNEXMR SCORING system
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Ovarian Carcinoma;   Refractory Pancreatic Carcinoma;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Intervention:   Drug: TRPV6 Calcium Channel Inhibitor SOR-C13
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRAF Gene Mutation;   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   RAS Family Gene Mutation;   Recurrent Thyroid Gland Carcinoma;   Refractory Thyroid Gland Carcinoma;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
    Interventions:   Procedure: Computed Tomography;   Radiation: Iodine I 124;   Radiation: Iodine I-131;   Other: Laboratory Biomarker Analysis;   Other: Pharmacodynamic Study;   Procedure: Positron Emission Tomography;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   ENSAT Stage I Adrenal Cortex Carcinoma;   ENSAT Stage II Adrenal Cortex Carcinoma;   ENSAT Stage III Adrenal Cortex Carcinoma
    Interventions:   Drug: Cisplatin;   Drug: Etoposide;   Drug: Mitotane;   Procedure: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Amercian Australian Asian Adrenal Alliance (A5);   European Network for the Study of Adrenal Tumors (ENS@T)
    Recruiting

  • Conditions:   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Surgical Procedure
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pituitary Neoplasm
    Intervention:   Other: ESC
    Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Malignant Solid Neoplasm;   Pancreatic Ductal Adenocarcinoma;   Progesterone Receptor Negative;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Recurrent Lymphoma;   Refractory Lymphoma;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
    Interventions:   Drug: Oxidative Phosphorylation Inhibitor IACS-010759;   Other: Pharmacodynamic Study;   Other: Pharmacokinetic Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anatomic Stage II Breast Cancer;   Anatomic Stage IIA Breast Cancer;   Anatomic Stage IIB Breast Cancer;   Anatomic Stage III Breast Cancer;   Anatomic Stage IIIA Breast Cancer;   Anatomic Stage IIIB Breast Cancer;   Anatomic Stage IIIC Breast Cancer;   Clinical Stage II Esophageal Adenocarcinoma;   Clinical Stage II Esophageal Squamous Cell Carcinoma;   Clinical Stage II Gastric Cancer;   Clinical Stage II Gastroesophageal Junction Adenocarcinoma;   Clinical Stage IIA Esophageal Adenocarcinoma;   Clinical Stage IIA Gastric Cancer;   Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma;   Clinical Stage IIB Esophageal Adenocarcinoma;   Clinical Stage IIB Gastric Cancer;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma;   Clinical Stage III Esophageal Adenocarcinoma;   Clinical Stage III Esophageal Squamous Cell Carcinoma;   Clinical Stage III Gastric Cancer;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma;   Distal Esophagus Squamous Cell Carcinoma;   Esophageal Carcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Limited Stage Small Cell Lung Carcinoma;   Malignant Solid Neoplasm;   Non-Small Cell Lung Carcinoma;   Pancreatic Adenocarcinoma;   Pathologic Stage II Esophageal Adenocarcinoma;   Pathologic Stage II Esophageal Squamous Cell Carcinoma;   Pathologic Stage II Gastric Cancer;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIA Esophageal Adenocarcinoma;   Pathologic Stage IIA Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIA Gastric Cancer;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIB Esophageal Adenocarcinoma;   Pathologic Stage IIB Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIB Gastric Cancer;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage III Esophageal Adenocarcinoma;   Pathologic Stage III Esophageal Squamous Cell Carcinoma;   Pathologic Stage III Gastric Cancer;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIA Esophageal Adenocarcinoma;   Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIIA Gastric Cancer;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIB Esophageal Adenocarcinoma;   Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIIB Gastric Cancer;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIC Gastric Cancer;   Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage II Gastric Cancer;   Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage III Gastric Cancer;   Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma;   Progesterone Receptor Negative;   Prognostic Stage II Breast Cancer;   Prognostic Stage IIA Breast Cancer;   Prognostic Stage IIB Breast Cancer;   Prognostic Stage III Breast Cancer;   Prognostic Stage IIIA Breast Cancer;   Prognostic Stage IIIB Breast Cancer;   Prognostic Stage IIIC Breast Cancer;   Stage I Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage II Lung Cancer;   Stage II Pancreatic Cancer;   Stage IIA Lung Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Lung Cancer;   Stage IIB Pancreatic Cancer;   Stage III Lung Cancer;   Stage IIIA Lung Cancer;   Stage IIIB Lung Cancer;   Stage IIIC Lung Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Ifetroban Sodium;   Other: Placebo
    Sponsors:   Vanderbilt-Ingram Cancer Center;   Cumberland Pharmaceuticals
    Recruiting

  • Conditions:   Diabetes Mellitus, Type 2;   PreDiabetes;   Pancreas Cyst;   Chronic Pancreatitis;   Genetic Predisposition to Disease;   Inherited Disease
    Interventions:   Diagnostic Test: Mixed Meal Tolerance Test;   Diagnostic Test: Hemoglobin A1c;   Diagnostic Test: Other exploratory blood biomarkers
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Liver Carcinoma;   Malignant Pancreatic Neoplasm;   Prostate Carcinoma
    Interventions:   Device: Cone-Beam Computed Tomography;   Radiation: 3-Dimensional Ultrasound-Guided Radiation Therapy
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Gastric Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma;   Non-Resectable Cholangiocarcinoma;   Stage IV Colorectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer;   Unresectable Pancreatic Carcinoma
    Interventions:   Drug: Nanoliposomal Irinotecan;   Drug: Trifluridine and Tipiracil Hydrochloride
    Sponsors:   Emory University;   Taiho Oncology, Inc.;   Ipsen
    Recruiting

  • Conditions:   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Colorectal Adenocarcinoma;   Oligometastasis;   Ovarian Carcinosarcoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Ovarian Carcinoma;   Refractory Colorectal Carcinoma;   Refractory Ovarian Carcinoma;   Stage IV Colorectal Cancer AJCC v8
    Interventions:   Biological: Autologous Tumor Infiltrating Lymphocytes MDA-TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Biological: Interleukin-2;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Conditions:   Colon Carcinoma Metastatic in the Liver;   Colorectal Adenocarcinoma;   Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma;   Stage I Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Colorectal Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
    Interventions:   Biological: Anti-SEMA4D Monoclonal Antibody VX15/2503;   Biological: Ipilimumab;   Biological: Nivolumab;   Procedure: Surgery
    Sponsors:   Emory University;   Vaccinex Inc.
    Recruiting

  • Conditions:   Cancer, All Types;   Cancer of Liver;   Cancer of Stomach;   Cancer of Head and Neck;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Colon;   Cancer Skin;   Cancer of Cervix;   Cancer, Metastatic;   Cancer of Larynx;   Cancer of Neck;   Cancer of Lung;   Cancer of Brain and Nervous System;   Cancer of Vulva, Disseminated;   Cancer of Pancreas;   Sarcoma;   GIST;   Small-cell Lung Cancer;   Adenocarcinoma Lung;   Cancer of Prostate;   Cancer, Advanced;   Adrenal Cancer;   Testicular Cancer;   Uterine Cancer;   Bronchoalveolar Cell Lung Cancer;   Cancer Unknown Primary;   Glioblastoma Multiforme;   Oligodendroglioma;   Breast Cancer;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Cholangiocarcinoma;   Squamous Cell Carcinoma;   Transitional Cell Carcinoma;   Cancer, Other;   Cancer, Anal;   Melanoma;   Cancer, Bile Duct;   Cancer, Bladder;   Cancer Cords Vocal;   Cancers Cell Neuroendocrine;   Cancer Differentiated Poorly;   Cancer, Anaplastic Thyroid
    Intervention:  
    Sponsors:   SpeciCare;   Dana-Farber Cancer Institute;   Kalispell Regional Medical Center;   Georgia Institute of Technology;   Ontario Institute for Cancer Research;   SEngine Precision Medicine;   Helomics
    Recruiting

  • Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Endometrial Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progressive Disease;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Copanlisib;   Drug: Niraparib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Resectable Pancreatic Ductal Adenocarcinoma;   Stage 0 Pancreatic Cancer AJCC v8;   Stage I Pancreatic Cancer AJCC v8;   Stage IA Pancreatic Cancer AJCC v8;   Stage IB Pancreatic Cancer AJCC v8;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8
    Interventions:   Drug: Cobimetinib;   Drug: Olaparib
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Neoplasms
    Intervention:   Other: blood and bile
    Sponsor:   Florida Hospital
    Recruiting

  • Conditions:   Carcinoma of Unknown Primary Origin;   Kidney Medullary Carcinoma;   Malignant Germ Cell Tumor;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Paraganglioma;   Metastatic Penile Carcinoma;   Paraganglioma;   Skin Squamous Cell Carcinoma;   Small Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Solid Neoplasm;   Vascular Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   KRAS Gene Mutation;   Malignant Female Reproductive System Neoplasm;   Metastatic Malignant Solid Neoplasm;   NRAS Gene Mutation;   Recurrent Lung Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Pancreatic Carcinoma;   Stage III Lung Cancer AJCC v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IV Lung Cancer AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Unresectable Malignant Solid Neoplasm
    Interventions:   Biological: Navitoclax;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage I Pancreatic Cancer AJCC v6 and v7;   Stage IA Pancreatic Cancer AJCC v6 and v7;   Stage IB Pancreatic Cancer AJCC v6 and v7;   Stage II Pancreatic Cancer AJCC v6 and v7;   Stage IIA Pancreatic Cancer AJCC v6 and v7;   Stage IIB Pancreatic Cancer AJCC v6 and v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IV Pancreatic Cancer AJCC v6 and v7
    Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Body Radiation Therapy;   Drug: Zoledronic Acid
    Sponsors:   Chi Lin, MD;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Ovarian Cancer;   Recurrent Fallopian Tube Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Relacorilant, 100mg QD;   Drug: Nab-paclitaxel, 80mg/m^2;   Drug: Nab-paclitaxel, 100mg/m^2;   Drug: Relacorilant, 150mg QD
    Sponsor:   Corcept Therapeutics
    Recruiting

  • Conditions:   Mesothelioma;   Thymoma;   Pancreatic Neoplasms;   Biliary Tract Neoplasms;   Stomach Neoplasms
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Adenocarcinoma
    Intervention:   Drug: Retrograde venous infusion of gemcitabine/lipiodol
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Not yet recruiting

  • Conditions:   Cancer of Pancreas;   Cancer of Pelvis;   Cancer of Abdomen;   Cancer of Thorax
    Intervention:   Device: Ring gantry kV-CBCT combined with linear accelerator
    Sponsors:   Washington University School of Medicine;   Varian Medical Systems
    Recruiting

  • Conditions:   Thyroid Cancer;   Graves Disease
    Intervention:   Device: Cervical Collar Therapy Indicator (COTI)
    Sponsor:   Johns Hopkins University
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Adenocarcinoma;   Familial Pancreatic Cancer;   BRCA 1/2;   HNPCC;   Lynch Syndrome;   Hereditary Pancreatitis;   FAMMM;   Familial Atypical Multiple Mole Melanoma;   Peutz Jeghers Syndrome
    Interventions:   Procedure: Endoscopic Ultrasound;   Procedure: Magnetic Resonance Imaging (MRI)
    Sponsor:   White Plains Hospital
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: oral azacitidine;   Other: Observation;   Drug: First-line chemotherapy after recurrence
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Colorectal Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIB Colorectal Cancer;   Stage IV Colorectal Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colorectal Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Colorectal Cancer;   Stage IVB Pancreatic Cancer;   Unresectable Pancreatic Carcinoma
    Interventions:   Drug: XL888;   Biological: Pembrolizumab
    Sponsors:   Emory University;   Merck Sharp & Dohme Corp.;   Exelixis
    Recruiting

  • Condition:   Hereditary Breast and Ovarian Cancer
    Interventions:   Behavioral: BRCA-Gist;   Behavioral: NCI Arm
    Sponsors:   Georgetown University;   Virginia Commonwealth University
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

  • Conditions:   Advanced Digestive System Neuroendocrine Neoplasm;   Digestive System Neuroendocrine Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Neoplasm;   Midgut Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor;   Refractory Digestive System Neuroendocrine Neoplasm
    Intervention:   Drug: Abemaciclib
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Pheochromocytoma;   Endocrine Disease;   Endocrine Diseases
    Interventions:   Drug: Fluorodopamine;   Drug: F-18 Fluorodopa
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Extrahepatic Bile Duct Adenocarcinoma, Biliary Type;   Gallbladder Adenocarcinoma, Biliary Type;   Metastatic Pancreatic Adenocarcinoma;   Recurrent Cholangiocarcinoma;   Recurrent Gallbladder Carcinoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Intrahepatic Cholangiocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Gallbladder Cancer AJCC V7;   Stage III Hepatocellular Carcinoma AJCC v7;   Stage III Intrahepatic Cholangiocarcinoma AJCC v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IIIA Gallbladder Cancer AJCC v7;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIB Gallbladder Cancer AJCC v7;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Gallbladder Cancer AJCC v7;   Stage IV Hepatocellular Carcinoma AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Stage IVA Gallbladder Cancer AJCC v7;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7;   Stage IVB Gallbladder Cancer AJCC v7;   Stage IVB Hepatocellular Carcinoma AJCC v7;   Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7;   Unresectable Gallbladder Carcinoma;   Unresectable Pancreatic Carcinoma
    Interventions:   Biological: Durvalumab;   Drug: Guadecitabine
    Sponsors:   University of Southern California;   National Cancer Institute (NCI);   Van Andel Research Institute
    Recruiting

  • Condition:   Differentiated Thyroid Cancer
    Interventions:   Drug: Cabozantinib;   Drug: Placebo
    Sponsor:   Exelixis
    Recruiting

  • Condition:   Thyroid Cancer
    Interventions:   Drug: Durvalumab (Medi4736);   Radiation: Radioiodine (RAI)
    Sponsors:   Memorial Sloan Kettering Cancer Center;   AstraZeneca;   MedImmune LLC
    Recruiting

  • Conditions:   Malignant Solid Tumors;   Lymphoma;   Ovarian Cancer
    Interventions:   Drug: AZD5153;   Drug: Olaparib
    Sponsor:   AstraZeneca
    Recruiting

  • Conditions:   CNS Tumors;   Meningioma;   Esthesioneuroblastoma;   Hemangioblastoma;   Medulloblastoma;   Paraganglioma;   Pituitary Adenoma
    Intervention:   Diagnostic Test: Ga68-DOTATATE-PET/MRI
    Sponsors:   Weill Medical College of Cornell University;   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   High Grade Ovarian Serous Adenocarcinoma;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
    Interventions:   Other: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Lavage;   Other: Pap Smear
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   Minnesota Ovarian Cancer Alliance
    Recruiting

  • Conditions:   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Clear Cell Tumor;   Malignant Ovarian Endometrioid Tumor;   Malignant Ovarian Serous Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment;   Drug: Topotecan Hydrochloride
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Behavioral: Questionnaires
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Breast Cancer;   Pancreas Cancer;   Prostate Cancer;   Lung Cancer;   Colon Cancer;   Esophagus Cancer;   Liver Cancer;   Ovary Cancer;   Lymphoma
    Intervention:   Drug: NP-G2-044
    Sponsors:   Novita Pharmaceuticals, Inc.;   Translational Drug Development
    Recruiting

  • Conditions:   Advanced Solid Tumors;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
    Interventions:   Drug: FT500;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Fate Therapeutics
    Recruiting

  • Conditions:   Locally Advanced Digestive System Neuroendocrine Carcinoma;   Locally Advanced Pancreatic Neuroendocrine Carcinoma;   Metastatic Digestive System Neuroendocrine Carcinoma;   Metastatic Pancreatic Neuroendocrine Carcinoma;   Refractory Digestive System Neuroendocrine Carcinoma;   Refractory Pancreatic Neuroendocrine Carcinoma;   Unresectable Digestive System Neuroendocrine Carcinoma;   Unresectable Pancreatic Neuroendocrine Carcinoma
    Interventions:   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Liposomal Irinotecan;   Procedure: Quality-of-Life Assessment
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Ipsen
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Brain Glioblastoma;   Estrogen Receptor Negative;   Extensive Stage Small Cell Lung Carcinoma;   Head and Neck Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Limited Stage Small Cell Lung Carcinoma;   Myelodysplastic Syndrome;   Progesterone Receptor Negative;   Progressive Disease;   Recurrent Carcinoma;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage III Colon Cancer;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage III Non-Small Cell Lung Cancer;   Stage III Ovarian Cancer;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Skin Melanoma;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Bladder Cancer;   Stage IV Bone Sarcoma;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IV Soft Tissue Sarcoma;   Stage IVA Bone Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Bone Sarcoma;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Procedure: Supportive Care;   Other: Survey Administration
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Parathyroid Gland Adenoma;   Parathyroid Gland Atypical Adenoma;   Parathyroid Gland Carcinoma;   Primary Hyperparathyroidism
    Interventions:   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer Survivor;   Current Smoker;   Former Smoker;   Malignant Head and Neck Neoplasm;   Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Neck;   Metastatic Malignant Neoplasm in the Uterine Cervix;   Pancreatic Adenocarcinoma;   Pancreatic Cyst;   Pancreatic Neuroendocrine Carcinoma;   Recurrent Colorectal Carcinoma;   Stage I Colorectal Cancer AJCC v6 and v7;   Stage I Hypopharyngeal Carcinoma AJCC v7;   Stage I Major Salivary Gland Cancer AJCC v7;   Stage I Nasopharyngeal Carcinoma AJCC v7;   Stage I Oral Cavity Cancer AJCC v6 and v7;   Stage I Oropharyngeal Carcinoma AJCC v6 and v7;   Stage II Colorectal Cancer AJCC v7;   Stage II Hypopharyngeal Carcinoma AJCC v6 and v7;   Stage II Major Salivary Gland Cancer AJCC v7;   Stage II Nasopharyngeal Carcinoma AJCC v7;   Stage II Oral Cavity Cancer AJCC v6 and v7;   Stage II Oropharyngeal Carcinoma AJCC v6 and v7;   Stage IIA Colorectal Cancer AJCC v7;   Stage IIB Colorectal Cancer AJCC v7;   Stage IIC Colorectal Cancer AJCC v7;   Stage III Colorectal Cancer AJCC v7;   Stage III Hypopharyngeal Carcinoma AJCC v7;   Stage III Laryngeal Cancer AJCC v6 and v7;   Stage III Major Salivary Gland Cancer AJCC v7;   Stage III Nasopharyngeal Carcinoma AJCC v7;   Stage III Oral Cavity Cancer AJCC v6 and v7;   Stage III Oropharyngeal Carcinoma AJCC v7;   Stage IIIA Colorectal Cancer AJCC v7;   Stage IIIB Colorectal Cancer AJCC v7;   Stage IIIC Colorectal Cancer AJCC v7;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVA Hypopharyngeal Carcinoma AJCC v7;   Stage IVA Laryngeal Cancer AJCC v7;   Stage IVA Major Salivary Gland Cancer AJCC v7;   Stage IVA Nasopharyngeal Carcinoma AJCC v7;   Stage IVA Oral Cavity Cancer AJCC v6 and v7;   Stage IVA Oropharyngeal Carcinoma AJCC v7;   Stage IVB Colorectal Cancer AJCC v7;   Stage IVB Hypopharyngeal Carcinoma AJCC v7;   Stage IVB Laryngeal Cancer AJCC v7;   Stage IVB Major Salivary Gland Cancer AJCC v7;   Stage IVB Nasopharyngeal Carcinoma AJCC v7;   Stage IVB Oral Cavity Cancer AJCC v6 and v7;   Stage IVB Oropharyngeal Carcinoma AJCC v7
    Interventions:   Behavioral: Exercise Intervention;   Other: Health Telemonitoring;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Device: Directional Brachytherapy Source Implant
    Sponsor:   CivaTech Oncology
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Pembrolizumab;   Radiation: Neoadjuvant Chemoradiation
    Sponsor:   Craig L Slingluff, Jr
    Recruiting

  • Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Metastatic Endometrioid Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
    Interventions:   Procedure: Biopsy;   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Planar Imaging;   Procedure: Single Photon Emission Computed Tomography;   Drug: Technetium Tc-99m Sodium Pertechnetate;   Biological: VSV-hIFNbeta-NIS
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Breast Cancer;   Stomach Neoplasms;   Salivary Gland Neoplasms;   Thyroid Cancer
    Intervention:  
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Recurrent Ovarian Carcinoma;   Platinum-resistant Ovarian Cancer
    Interventions:   Diagnostic Test: ChemoID Assay;   Drug: Standard Chemotherapy
    Sponsor:   Cordgenics, LLC
    Recruiting

  • Conditions:   Ovarian Cancer;   Prostate Cancer;   Pancreas Cancer
    Intervention:   Behavioral: Assessments
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
    Interventions:   Drug: Olaparib;   Drug: Tremelimumab
    Sponsor:   New Mexico Cancer Care Alliance
    Recruiting

  • Conditions:   Metastatic Pancreatic Cancer;   Unresectable Pancreatic Cancer;   Metastatic Colorectal Cancer
    Interventions:   Behavioral: Usual chemotherapy education (CE);   Behavioral: Chemotherapy education intervention (CEI)
    Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Fallopian Tube Cancer;   Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Entinostat;   Drug: Olaparib
    Sponsors:   Vanderbilt-Ingram Cancer Center;   AstraZeneca;   Syndax Pharmaceuticals
    Not yet recruiting

  • Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   High-Frequency Microsatellite Instability;   Locally Advanced Urothelial Carcinoma;   Metastatic Gastric Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Metastatic Head and Neck Squamous Cell Carcinoma;   Metastatic Lung Non-Small Cell Carcinoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Melanoma;   Metastatic Pancreatic Adenocarcinoma;   Metastatic Urothelial Carcinoma;   Mismatch Repair Deficiency;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   PD-L1 Positive;   Progressive Disease;   Recurrent Head and Neck Squamous Cell Carcinoma;   Refractory Lung Non-Small Cell Carcinoma;   Refractory Pancreatic Adenocarcinoma;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Unresectable Malignant Solid Neoplasm;   Unresectable Melanoma;   Unresectable Pancreatic Adenocarcinoma
    Interventions:   Biological: Pembrolizumab;   Drug: Sonidegib
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Fecal Incontinence;   Low Anterior Resection Syndrome;   Malignant Anal Neoplasm;   Malignant Bladder Neoplasm;   Malignant Cervical Neoplasm;   Malignant Ovarian Neoplasm;   Malignant Pelvic Neoplasm;   Malignant Prostate Neoplasm;   Malignant Uterine Neoplasm;   Malignant Vaginal Neoplasm;   Malignant Vulvar Neoplasm;   Rectal Adenocarcinoma;   Stage III Rectal Cancer AJCC v8;   Stage IIIA Rectal Cancer AJCC v8;   Stage IIIB Rectal Cancer AJCC v8;   Stage IIIC Rectal Cancer AJCC v8;   Stage IV Rectal Cancer AJCC v8;   Stage IVA Rectal Cancer AJCC v8;   Stage IVB Rectal Cancer AJCC v8;   Stage IVC Rectal Cancer AJCC v8
    Interventions:   Procedure: Explantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Device: Sacral Nerve Stimulator;   Device: Sacral Nerve Stimulator Battery;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Breast Carcinoma;   Fallopian Tube Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Solid Neoplasm
    Interventions:   Procedure: Computed Tomography;   Radiation: Fludeoxyglucose F-18;   Radiation: Fluorine F 18 Fluorthanatrace;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer;   Cholangiocarcinoma;   Pancreatic Cancer;   Metastatic Pancreatic Cancer
    Interventions:   Drug: Entinostat;   Drug: Nivolumab
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Syndax Pharmaceuticals;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Panhypopituitarism;   Gigantism/Acromegaly;   Prolactinoma;   Cushing Disease
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Locally Advanced Pancreatic Cancer;   Locally Advanced Malignant Solid Neoplasm;   Metastatic Malignant Solid Neoplasm;   Metastatic Renal Cell Carcinoma;   Metastatic Urothelial Carcinoma;   Metastatic Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: ATR Kinase Inhibitor AZD6738;   Drug: Olaparib
    Sponsors:   Rahul Aggarwal;   AstraZeneca
    Recruiting

  • Conditions:   Medullary Thyroid Cancer;   Infantile Myofibromatosis;   Infantile Fibrosarcoma;   Papillary Thyroid Cancer;   Soft Tissue Sarcoma
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Ductal Carcinoma;   Esophageal Squamous Cell Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Breast Cancer;   Other Solid Tumors
    Intervention:   Drug: JAB-3312
    Sponsor:   Jacobio Pharmaceuticals Co., Ltd.
    Recruiting

  • Conditions:   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8;   Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8;   Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8;   Thyroid Gland Anaplastic Carcinoma;   Unresectable Thyroid Gland Carcinoma
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Cobimetinib;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Drug: Vemurafenib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Uterine Corpus Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Cancer;   Recurrent Primary Peritoneal Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
    Interventions:   Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Colon Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Pancreatic Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Laboratory Procedure
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hypogonadism, Male;   Fatigue Syndrome, Chronic
    Interventions:   Drug: Testosterone cypionate 125 mg/week;   Other: placebo
    Sponsor:   Seattle Institute for Biomedical and Clinical Research
    Not yet recruiting

  • Conditions:   Colorectal Cancer;   Esophageal Cancer;   Gastric Cancer;   Pancreatic Cancer;   Precancerous Condition
    Interventions:   Genetic: protein analysis;   Genetic: proteomic profiling;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis;   Other: medical chart review;   Procedure: diagnostic colonoscopy;   Procedure: diagnostic endoscopic procedure;   Procedure: diagnostic endoscopic surgery;   Procedure: diagnostic surgical procedure;   Procedure: endoscopic surgery;   Procedure: screening colonoscopy
    Sponsors:   Vanderbilt University Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: FOLFIRINOX;   Drug: Losartan;   Drug: Nivolumab;   Radiation: SBRT;   Procedure: Surgery
    Sponsors:   Massachusetts General Hospital;   Bristol-Myers Squibb;   Stand Up To Cancer
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Ampulla of Vater Adenocarcinoma;   Cholangiocarcinoma;   Duodenal Adenocarcinoma;   Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type;   Periampullary Adenocarcinoma
    Interventions:   Procedure: Pancreatectomy;   Other: Lavage
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Adrenocortical Tumor
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Thyroid Gland Nodule
    Intervention:   Other: Diagnostic DNA Methylation Signature
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HER2 Positive Gastric Cancer;   Colorectal Cancer;   Head and Neck Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   Advanced Solid Tumors;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer
    Interventions:   Drug: FATE-NK100;   Drug: Cetuximab;   Drug: Trastuzumab
    Sponsor:   Fate Therapeutics
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Niraparib Treatment
    Sponsors:   University of Kansas Medical Center;   Tesaro, Inc.
    Recruiting

  • Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Stage I Uterine Corpus Cancer;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer;   Uterine Corpus Carcinosarcoma;   Uterine Corpus Sarcoma
    Interventions:   Radiation: Vaginal Cuff Brachytherapy;   Radiation: Short course vaginal cuff brachytherapy
    Sponsor:   University of Utah
    Recruiting

  • Condition:   Cancer - Ovarian
    Interventions:   Drug: Veliparib, capsule;   Drug: Veliparib, tablet;   Drug: Carboplatin;   Drug: Paclitaxel
    Sponsor:   AbbVie
    Not yet recruiting

  • Conditions:   Melanoma;   Cervical Carcinoma;   Pancreatic Carcinoma;   Triple Negative Breast Cancer;   Hepatocellular Carcinoma;   Urothelial Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Nasopharyngeal Carcinoma;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Non-small Cell Lung Carcinoma;   Small Cell Lung Carcinoma;   Gastric or Gastroesophageal Junction Adenocarcinoma;   Advanced or Metastatic Solid Tumors;   Prostate Carcinoma;   MSI-H;   Mismatch Repair Deficiency
    Interventions:   Biological: XmAb®22841;   Biological: Pembrolizumab (Keytruda®)
    Sponsors:   Xencor, Inc.;   ICON Clinical Research
    Recruiting

  • Conditions:   Pancreatic Cyst;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Cystadenoma, Mucinous;   Papillary Mucinous Cystadenoma, Borderline Malignancy
    Intervention:   Procedure: 98% Ethanol & Paclitaxel injection
    Sponsor:   Indiana University
    Recruiting

  • Conditions:   Pancreatic Neoplasms;   Pancreatitis;   Pancreatic Cyst
    Intervention:   Other: EUS enhanced with contrast to evaluate pancreas
    Sponsor:   University of Southern California
    Recruiting

  • Condition:   Pancreatic Neoplasm
    Intervention:   Drug: Antroquinonol
    Sponsors:   Golden Biotechnology Corporation;   Covance
    Recruiting

  • Conditions:   Advanced or Metastatic Solid Tumors;   Head and Neck Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer
    Intervention:   Drug: NC318
    Sponsor:   NextCure, Inc.
    Recruiting

  • Conditions:   Stage III Fallopian Tube Cancer AJCC v7;   Stage III Ovarian Cancer AJCC v6 and v7;   Stage III Primary Peritoneal Cancer AJCC v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer;   Risk of Premature Ovarian Failure;   Fertility Preservation
    Intervention:   Procedure: surgery to remove ovaries or high dose chemotherapy
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Advanced Platinum-resistant Ovarian Cancer;   Advanced Platinum-resistant Fallopian Tube Cancer;   Advanced Platinum-resistant Primary Peritoneal Cancer
    Interventions:   Drug: REGN4018;   Drug: cemiplimab
    Sponsor:   Regeneron Pharmaceuticals
    Recruiting

  • Conditions:   Borderline Resectable Pancreatic Adenocarcinoma;   Locally Advanced Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Stage II Pancreatic Cancer AJCC v6 and v7;   Stage IIA Pancreatic Cancer AJCC v6 and v7;   Stage IIB Pancreatic Cancer AJCC v6 and v7;   Stage III Pancreatic Cancer AJCC v6 and v7
    Interventions:   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Drug: AVB-S6-500;   Drug: Paclitaxel (Pac);   Drug: Pegylated liposomal doxorubicin (PLD);   Other: Placebo
    Sponsor:   Aravive, Inc.
    Recruiting

  • Conditions:   Kidney Medullary Carcinoma;   Loss of INI 1 Protein Expression;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Anetumab Ravtansine;   Biological: Bevacizumab;   Drug: Paclitaxel
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Advanced Ovarian Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Durvalumab;   Drug: Olaparib;   Drug: Placebo olaparib;   Drug: Durvalumab placebo;   Drug: Carboplatin+Paclitaxel
    Sponsors:   AstraZeneca;   European Network of Gynaecological Oncological Trial Groups (ENGOT);   GOG Foundation, Inc. (GOG Foundation);   Myriad Genetic Laboratories, Inc.
    Recruiting

  • Condition:   Pancreatic Cancer Non-resectable
    Interventions:   Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel;   Drug: Placebo + Gemcitabine + Nab-paclitaxel
    Sponsor:   FibroGen
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Drug: NUC-1031 500 mg;   Drug: NUC-1031 750mg
    Sponsor:   NuCana plc
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus);   Drug: Capecitabine, Gemcitabine, and 5-FU
    Sponsor:   Tyme, Inc
    Recruiting

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Estrogen-receptor Positive Breast Cancer;   Cancer, Breast;   Breast Cancer Female;   Breast Adenocarcinoma;   Estrogen Receptor Positive Tumor;   ER Positive
    Intervention:   Drug: H3B-6545
    Sponsors:   H3 Biomedicine Inc.;   Eisai Inc.
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Behavioral: Questionnaire;   Procedure: CA 125 Analysis;   Procedure: Transvaginal Ultrasound
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Golfers Against Cancer
    Recruiting

  • Conditions:   Cancer;   Lymphoma;   Pancreatic Cancer;   Glioblastoma Multiforme;   Sarcoma;   Breast Cancer;   Bladder Cancer;   Renal Cancer;   Ovarian Cancer;   Refractory Cancer;   Refractory Neoplasm;   Refractory Non-Hodgkin Lymphoma;   Refractory Brain Tumor;   Pancreatic Adenocarcinoma;   Resistant Cancer;   Neoplasm Metastasis;   Neoplasm of Bone;   Neoplasm, Breast;   Neoplasm of Lung;   Neoplasms,Colorectal;   Neoplasms Pancreatic;   Malignant Glioma;   Malignancies;   Malignancies Multiple;   Bone Metastases;   Bone Neoplasm;   Bone Cancer;   Pancreas Cancer;   Pancreatic Neoplasms;   Breast Neoplasms
    Interventions:   Drug: 9-ING-41;   Drug: Gemcitabine - 21 day cycle;   Drug: Doxorubicin.;   Drug: Lomustine;   Drug: Carboplatin.;   Drug: Nab paclitaxel.;   Drug: Paclitaxel.;   Drug: Gemcitabine - 28 day cycle
    Sponsors:   Actuate Therapeutics Inc.;   Developmental Therapeutics Consortium
    Recruiting

  • Conditions:   Pancreas Cancer;   Pancreatitis;   Chronic Pancreatitis;   Pancreatic Cyst;   Family History of Pancreas Cancer;   Genetic Mutations
    Intervention:  
    Sponsor:   Icahn School of Medicine at Mount Sinai
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Drug: OTL38;   Device: near infrared imaging
    Sponsors:   On Target Laboratories, LLC;   SynteractHCR
    Recruiting

  • Condition:   Recurrent Platinum Resistant Ovarian Cancer
    Interventions:   Drug: VB-111 + Paclitaxel;   Drug: Placebo + Paclitaxel
    Sponsors:   Vascular Biogenics Ltd. operating as VBL Therapeutics;   GOG Foundation, Inc.
    Recruiting

  • Condition:   OVARIAN CANCER
    Interventions:   Drug: Cobimetinib;   Drug: Niraparib;   Drug: Atezolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Radiation: Hypofractionated ablative IMRT (HFA-IMRT);   Drug: capecitabine
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Ovarian Cancer
    Interventions:   Drug: Niraparib;   Drug: TSR-042;   Drug: Placebo
    Sponsors:   Tesaro, Inc.;   European Network of Gynaecological Oncological Trial Groups (ENGOT)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: mFOLFIRINOX;   Drug: Ramucirumab;   Other: Placebo
    Sponsors:   Walid Shaib, MD;   Eli Lilly and Company;   Hoosier Cancer Research Network
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Biological: Pegilodecakin;   Drug: FOLFOX
    Sponsors:   Eli Lilly and Company;   ARMO BioSciences
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Oxaliplatin;   Radiation: SBRT;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: 5FU
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Breast Cancer;   Hereditary Breast and Ovarian Cancer
    Intervention:  
    Sponsor:   University of Kansas Medical Center
    Recruiting

  • Condition:   Advanced Pancreatic Cancer
    Interventions:   Biological: Cabiralizumab;   Drug: Nab-paclitaxel;   Drug: Onivyde;   Biological: Nivolumab;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: Irinotecan Hydrochloride
    Sponsor:   Bristol-Myers Squibb
    Recruiting

  • Condition:   Metastatic Pancreatic Cancer
    Interventions:   Drug: Olaratumab;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreas Adenocarcinoma;   Advanced Pancreatic Cancer;   Metastatic Pancreatic Cancer;   Metastatic Pancreatic Adenocarcinoma
    Interventions:   Drug: Pembrolizumab;   Drug: paricalcitol;   Drug: placebo
    Sponsors:   Translational Genomics Research Institute;   Stand Up To Cancer;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Recurrent Epithelial Ovarian Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Peritoneal Cancer
    Interventions:   Other: DPX-Survivac;   Drug: Cyclophosphamide;   Drug: Epacadostat (INCB024360)
    Sponsors:   ImmunoVaccine Technologies, Inc. (IMV Inc.);   Incyte Corporation
    Recruiting

  • Conditions:   Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content;   Head and Neck Cancer;   Non-small Cell Lung Cancer;   Gastric Cancer;   Esophageal Cancer;   Pancreas Cancer;   Bladder Cancer;   Renal Cell Carcinoma;   Melanoma;   Triple-negative Breast Cancer;   Ovarian Cancer;   Colo-rectal Cancer
    Intervention:   Drug: ADCT-301
    Sponsor:   ADC Therapeutics S.A.
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
    Intervention:   Drug: tisotumab vedotin
    Sponsors:   Seattle Genetics, Inc.;   Genmab
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma;   High Grade Serous Carcinoma;   Endometrioid Adenocarcinoma
    Interventions:   Drug: Rucaparib;   Drug: Nivolumab
    Sponsors:   Clovis Oncology, Inc.;   Bristol-Myers Squibb;   Foundation Medicine
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Biological: GEN-1;   Drug: Carboplatin;   Drug: Paclitaxel
    Sponsor:   Celsion
    Recruiting

  • Conditions:   Pheochromocytoma;   Paraganglioma;   Inherited Cancer Syndrome;   Associated Conditions;   Kidney Neoplasms;   Bone Cancer;   Thyroid Neoplasms;   Other Cancer
    Intervention:   Genetic: Genetic screening
    Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institute of General Medical Sciences (NIGMS)
    Recruiting

  • Conditions:   Granulosa Cell Ovarian Cancer;   Low Grade Serous Ovarian/ Primary Peritoneal Cancer;   Endometrioid Endometrial Cancer
    Intervention:   Drug: Onapristone ER
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Context Therapeutics
    Recruiting

  • Conditions:   Hyponatremia;   Hyponatremic;   Pituitary Tumor;   Pituitary;   Surgery
    Intervention:   Other: Fluid Restricted Group
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Thromboembolism of Vein VTE in Colorectal Cancer;   Thromboembolism of Vein in Pancreatic Cancer;   Thromboembolism of Vein in Non-small Cell Lung Cancer
    Intervention:   Drug: Isoquercetin
    Sponsors:   Jeffrey Zwicker, MD;   Quercegen Pharmaceuticals;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Carcinoma
    Interventions:   Drug: ribociclib;   Drug: Paclitaxel;   Drug: Carboplatin
    Sponsor:   Ronald Buckanovich
    Recruiting

  • Conditions:   Adnexal Mass;   Ovarian Cancer;   Pelvic Mass
    Intervention:  
    Sponsor:   Venn Biosciences Corporation
    Recruiting

  • Conditions:   Pancreatic Cancer;   Non-Small Cell Lung Cancer;   Cancer
    Interventions:   Drug: Avelumab;   Drug: Binimetinib;   Drug: Talazoparib
    Sponsors:   Pfizer;   Array BioPharma
    Recruiting

  • Conditions:   Genitourinary Cancer;   Adrenocortical Carcinoma;   Non-urothelial Bladder;   Non-urothelial Upper Tract;   Penile Cancer;   Non-adenocarcinoma Prostate Cancer;   Refractory Germ-cell
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting

  • Conditions:   Atypical Hyperplasia;   Endometrial Intraepithelial Neoplasia;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   Postmenopausal
    Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer;   Malignancy;   Neoplasia;   Neoplasm;   Neoplasm Metastasis;   Colon Cancer;   Colonic Neoplasms;   Colon Cancer Liver Metastasis;   Metastatic Cancer;   Metastatic Melanoma;   Metastatic Colon Cancer;   Metastatic Lung Cancer;   Non Small Cell Lung Cancer Metastatic;   Pancreatic Cancer;   Pancreas Cancer;   Pancreas Adenocarcinoma;   Pancreas Neoplasm;   Metastatic Nonsmall Cell Lung Cancer;   Metastatic Pancreatic Cancer
    Interventions:   Drug: ASN007: ascending doses;   Drug: ASN007 RD
    Sponsor:   Asana BioSciences
    Recruiting

  • Conditions:   Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
    Interventions:   Drug: Chemotherapy;   Drug: Rucaparib
    Sponsors:   Clovis Oncology, Inc.;   Foundation Medicine
    Recruiting

  • Conditions:   Pancreatic Ductal Adenocarcinoma;   Pancreatic Cancer;   Pancreatic Neoplasms
    Interventions:   Drug: PEGPH20;   Biological: Pembrolizumab
    Sponsors:   Pancreatic Cancer Research Team;   Merck Sharp & Dohme Corp.;   Halozyme Therapeutics;   University of Washington
    Recruiting

  • Conditions:   Germ Cell Tumor;   Testicular Tumor
    Interventions:   Behavioral: Questionnaires;   Other: sample of blood or saliva
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Pancreatic Cancer;   Cancer Cachexia
    Interventions:   Other: Blood Sample Collection;   Other: Tumor Sample collection;   Other: Data Collection
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Conditions:   Pancreatic Cancer Metastatic;   Pancreatic Cancer Stage IV;   Stage IV Pancreatic Cancer
    Interventions:   Drug: SBP-101;   Drug: nab-paclitaxel;   Drug: Gemcitabine Injection
    Sponsor:   Sun BioPharma Inc
    Recruiting

  • Conditions:   Endometrial Cancer;   Uterine Cancer;   Ovarian Cancer;   Carcinosarcoma
    Interventions:   Drug: Paclitaxel;   Drug: 300mg DKN-01;   Drug: 600mg DKN-01
    Sponsor:   Leap Therapeutics, Inc.
    Recruiting

  • Conditions:   Soft Tissue Sarcoma;   Colorectal Cancer;   Head and Neck Squamous Cell Carcinoma;   Non-small Cell Lung Carcinoma;   Breast Carcinoma;   Ovarian Carcinoma;   Exocrine Pancreatic Carcinoma;   Gastric Carcinoma;   Melanoma
    Intervention:   Drug: SGN-CD47M
    Sponsor:   Seattle Genetics, Inc.
    Recruiting

  • Condition:   Locally Advanced Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: nab-paclitaxel;   Device: RenovoCath
    Sponsor:   RenovoRx
    Recruiting

  • Conditions:   Solid Tumours Harboring NRG1 Fusion;   NSCLC Harboring NRG1 Fusion;   Pancreatic Cancer Harboring NRG1 Fusion;   NRG1 Fusion
    Intervention:   Drug: MCLA-128
    Sponsor:   Merus N.V.
    Recruiting

  • Conditions:   Pancreatic Cancer;   Metastatic Castration-resistant Prostate Cancer;   Bladder Cancer;   Melanoma;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Gastric Cancer;   Esophageal Cancer;   Ovarian Cancer;   Head Neck Squamous Cell Carcinoma
    Interventions:   Biological: NGM120;   Other: Placebo
    Sponsor:   NGM Biopharmaceuticals, Inc
    Not yet recruiting

  • Conditions:   Thyroid Cancer;   Squamous Cell Carcinoma Head and Neck Cancer (HNSCC);   HRAS Mutant Tumor;   Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor
    Intervention:   Drug: Tipifarnib
    Sponsor:   Kura Oncology, Inc.
    Recruiting

  • Conditions:   Pituitary;   Pituitary Tumor;   Pituitary Carcinoma;   Pituitary Cancer
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal;   Fallopian Tube Cancer;   Newly Diagnosed;   FIGO Stage III-IV;   Partial Response;   Complete Response
    Interventions:   Drug: Rucaparib;   Drug: Nivolumab;   Drug: Placebo Oral Tablet;   Drug: Placebo IV Infusion
    Sponsors:   Clovis Oncology, Inc.;   Bristol-Myers Squibb;   Gynecologic Oncology Group;   European Network of Gynaecological Oncological Trial Groups (ENGOT);   Foundation Medicine
    Recruiting

  • Conditions:   Small Cell Carcinoma;   Carcinoma, Non-Small-Cell Lung;   Neuroendocrine Tumors;   Ovarian Epithelial Cancer
    Interventions:   Drug: RRx-001;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Irinotecan;   Drug: Vinorelbine;   Drug: Doxil;   Drug: Gemcitabine;   Drug: Taxane;   Drug: Paclitaxel;   Drug: Nab-Paclitaxel;   Drug: Pemetrexed
    Sponsor:   EpicentRx, Inc.
    Recruiting

  • Conditions:   Pancreas Cancer;   Peutz-Jeghers Syndrome (PJS);   Gene Mutation;   Germline Mutation Carrier;   Lynch Syndrome
    Intervention:   Drug: Human synthetic secretin
    Sponsors:   Johns Hopkins University;   ChiRhoClin, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Ductal Adenocarcinoma;   Pancreatic Cancer
    Interventions:   Drug: siG12D-LODER;   Drug: Gemcitabine+nab-Paclitaxel
    Sponsor:   Silenseed Ltd
    Recruiting

  • Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breast Cancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer;   Neuroendocrine Tumors;   Plasma Cell Dyscrasia
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting

  • Conditions:   Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Pancreatic Neoplasms;   Colorectal Neoplasms
    Interventions:   Biological: V941;   Biological: Pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Breast Neoplasms;   Colorectal Neoplasms;   Pancreatic Neoplasms;   Ovarian Neoplasms
    Intervention:  
    Sponsors:   The Canadian College of Naturopathic Medicine;   Bastyr University;   Lotte & John Hecht Memorial Foundation
    Recruiting

  • Conditions:   Colorectal Cancer;   Pancreatic Adenocarcinoma;   Gastric Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Bladder Cancer;   Melanoma;   Ovarian Cancer;   Adrenocortical Cancer;   Breast Cancer;   Other Cancer
    Intervention:  
    Sponsor:   Quantgene Inc.
    Recruiting

  • Conditions:   Colorectal Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Exocrine Pancreatic Cancer;   Carcinoma, Squamous Cell of Head and Neck
    Intervention:   Drug: tisotumab vedotin
    Sponsors:   Seattle Genetics, Inc.;   Genmab
    Recruiting

  • Conditions:   Ovarian Cancer;   Cervical Cancer;   Endometrial Cancer;   Non Small Cell Lung Cancer;   Thyroid Cancer;   Melanoma;   Sarcoma
    Intervention:   Biological: Enapotamab vedotin (HuMax-AXL-ADC)
    Sponsor:   Genmab
    Recruiting

  • Condition:   Exocrine Pancreatic Insufficiency (EPI)
    Interventions:   Drug: Pancrelipase;   Drug: Placebo
    Sponsor:   AbbVie
    Not yet recruiting

  • Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Lung Non-Small Cell Carcinoma;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Stage I Lung Cancer AJCC v8;   Stage I Ovarian Cancer AJCC v8;   Stage IA Ovarian Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage IB Ovarian Cancer AJCC v8;   Stage IC Ovarian Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8
    Interventions:   Drug: Chemotherapy;   Other: Functional Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Biliary Tract Cancer (BTC);   Colorectal Cancer (CRC);   Endometrial Cancer;   Gastroesophageal Cancer (GC);   Ovarian Cancer;   Solid Tumors
    Interventions:   Drug: INCB001158;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-Fluorouracil;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Paclitaxel
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Pancreatic Ductal Adenocarcinoma;   Familial Pancreatic Cancer;   FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
    Intervention:  
    Sponsor:   Immunovia, Inc.
    Recruiting

  • Conditions:   Ovarian Cancer;   Ovarian Carcinoma;   Ovary Cancer;   Endometrial Cancer;   Endometrioid Adenocarcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
    Intervention:   Drug: STRO-002
    Sponsor:   Sutro Biopharma, Inc.
    Recruiting

  • Conditions:   Head and Neck Squamous Cell Carcinoma;   Breast Cancer;   Sarcoma;   Merkel Cell Carcinoma;   Cutaneous T-Cell Lymphoma;   Melanoma;   Renal Cancer;   Bladder Cancer;   Prostate Cancer;   Testicular Cancer;   Solid Tumor
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Poly ICLC
    Sponsors:   Ludwig Institute for Cancer Research;   MedImmune LLC;   Cancer Research Institute, New York City
    Recruiting

  • Conditions:   Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Diseases
    Interventions:   Drug: Cefoxitin;   Drug: Piperacillin-tazobactam
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Indiana University;   Massachusetts General Hospital;   Thomas Jefferson University;   Washington University School of Medicine;   Advocate Illinois Masonic Medical Center;   Baptist Memorial Health Care Corporation;   Baylor Scott and White Health;   The Cleveland Clinic;   Emory University;   Fox Chase Cancer Center;   Gundersen Lutheran Medical Center;   Hackensack Meridian Health;   Hamilton Health Sciences Center;   Intermountain Health Care, Inc.;   Jersey Shore Medical Center (Hackensack Meridian);   Johns Hopkins University;   Montefiore Medical Center/Albert Einstein College of Medicine;   NorthShore University HealthSystem;   Milton S. Hershey Medical Center;   Rhode Island Hospital;   Stony Brook Medicine;   Sunnybrook Health Sciences Centre, Canada;   Temple University;   The Ohio State University Wexner Medical Center;   The Ottowa Hospital/University of Ottowa;   University of California, Davis;   University of Chicago;   University of Iowa;   University of Texas Southwestern Medical Center;   University of Utah;   University of Wisconsin, Madison;   Providence Health & Services;   Albany Medical College;   Northwestern University;   Universtiy of Mississippi Medical Center;   Mount Sinai Hospital, New York;   Brody School of Medicine at East Carolina University
    Recruiting

  • Conditions:   Carcinomatosis;   Elevated Serum CA-125 Tumor Antigen;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Stage III Fallopian Tube Cancer AJCC v7;   Stage III Ovarian Cancer AJCC v6 and v7;   Stage III Primary Peritoneal Cancer AJCC v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
    Interventions:   Drug: Adavosertib;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Bone Lesion;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Brenner Tumor;   Malignant Ascites;   Malignant Pleural Effusion;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
    Interventions:   Drug: metformin hydrochloride;   Drug: placebo;   Drug: Chemotherapy
    Sponsor:   University of Chicago
    Recruiting

  • Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   FIGO Stage III Ovarian Cancer;   FIGO Stage IIIA Ovarian Cancer;   FIGO Stage IIIA1 Ovarian Cancer;   FIGO Stage IIIA2 Ovarian Cancer;   FIGO Stage IIIB Ovarian Cancer;   FIGO Stage IIIC Ovarian Cancer;   FIGO Stage IVA Ovarian Cancer;   FIGO Stage IVB Ovarian Cancer;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Stage III Fallopian Tube Cancer AJCC v7;   Stage III Primary Peritoneal Cancer AJCC v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Ruxolitinib;   Drug: Ruxolitinib Phosphate;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Ovarian Cancer
    Intervention:   Diagnostic Test: Circulating tumour DNA testing
    Sponsors:   Walter and Eliza Hall Institute of Medical Research;   Johns Hopkins University
    Recruiting

  • Conditions:   Triple Negative Breast Cancer;   Pancreatic Carcinoma;   Melanoma;   Endometrial Carcinoma
    Interventions:   Drug: MCS110;   Drug: PDR001
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Advanced Cancer;   Ovarian Cancer;   Breast Cancer;   Lung Cancer;   Endometrial Cancer;   Ovarian Neoplasm;   Triple Negative Breast Cancer;   Lung Neoplasm;   Neoplasm Malignant
    Interventions:   Drug: COM701;   Drug: COM701 with Opdivo (Nivolumab).
    Sponsors:   Compugen Ltd;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Solid Tumors;   Colorectal Cancer;   Breast Cancer;   Ovarian Cancer;   Colon Cancer;   Rectal Cancer;   Neoplasms;   Endometrial Cancer;   Soft Tissue Sarcoma;   Triple Negative Breast Cancer;   Pancreas Cancer;   Pancreatic Cancer
    Interventions:   Drug: LY2880070;   Drug: Gemcitabine
    Sponsor:   Esperas Pharma Inc.
    Recruiting

  • Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Ovarian Neoplasms;   Ovary Cancer;   Fallopian Tube Neoplasms;   Fallopian Tube Adenocarcinoma;   High Grade Serous Carcinoma;   Peritoneal Carcinoma;   Peritoneal Neoplasms;   Adnexal Mass;   Ovarian Diseases
    Intervention:   Device: Hysteroscopic cell sampling of the fallopian tube
    Sponsors:   nVision Medical;   Boston Scientific Corporation
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Breast Carcinoma;   Metastatic Malignant Solid Neoplasm;   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Malignant Solid Neoplasm
    Interventions:   Drug: Olaparib;   Drug: Onalespib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
    Intervention:   Drug: Entrectinib
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Radiation Therapy;   Cancer;   Cancer of Anus;   Cancer of Bladder;   Cancer of Cervix;   Cancer of Colon;   Cancer of Rectum;   Cancer of Esophagus;   Cancer of Gallbladder;   Cancer of Liver;   Cancer of Ovary;   Cancer of Pancreas;   Cancer of Prostate;   Cancer of Kidney and Renal Pelvis;   Cancer of Stomach;   Cancer of Testis;   Cancer of Uterus;   Cancer of Uterus and Cervix;   Cancer of Kidney
    Intervention:  
    Sponsors:   DxTerity Diagnostics;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage III Uterine Corpus Cancer AJCC v7;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Breast Cancer;   Prostate Cancer;   Ovarian Cancer
    Interventions:   Drug: Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib;   Drug: Part 1, Dose level 2b and dose level 3: Ipatasertib;   Drug: Part 1, Dose Level 1 and Dose Level 2b: Rucaparib;   Drug: Part 1, Dose Level 2a and Dose Level 3: Rucaparib
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Melanoma (Excluding Uveal Melanoma);   Cervical Carcinoma;   Pancreatic Carcinoma;   Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative;   Hepatocellular Carcinoma;   Urothelial Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Nasopharyngeal Carcinoma;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Non-small Cell Lung Carcinoma;   Small Cell Lung Cancer;   Gastric or Gastroesophageal Junction Adenocarcinoma;   Advanced Solid Tumors
    Intervention:   Biological: XmAb®23104
    Sponsors:   Xencor, Inc.;   ICON plc
    Recruiting

  • Conditions:   Gastrointestinal Cancer;   Gastrointestinal Neoplasms;   Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma;   Gastric Cancer;   Gastric Neoplasm;   Pancreatic Cancer;   Pancreatic Neoplasm
    Interventions:   Drug: RGX-202-01;   Drug: FOLFIRI
    Sponsor:   Rgenix, Inc.
    Recruiting

  • Conditions:   Stage III Ovarian Carcinoma;   Stage IV Ovarian Carcinoma;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
    Interventions:   Biological: AVOVA-1;   Biological: MC
    Sponsor:   Aivita Biomedical, Inc.
    Recruiting

  • Conditions:   Pancreatic Cancer;   Metastatic Pancreatic Cancer;   Metastatic Pancreatic Adenocarcinoma
    Interventions:   Drug: zolbetuximab;   Drug: nab-paclitaxel;   Drug: gemcitabine
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting

  • Conditions:   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
    Interventions:   Radiation: Iodine I-131;   Other: Placebo;   Drug: Selumetinib
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Progesterone Receptor Negative;   Stage III Breast Cancer AJCC v7;   Stage III Lung Non-Small Cell Cancer AJCC v7;   Stage III Lung Small Cell Carcinoma AJCC v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Small Cell Carcinoma AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Lung Small Cell Carcinoma AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Lung Non-Small Cell Cancer AJCC v7;   Stage IV Lung Small Cell Carcinoma AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma;   Unresectable Pancreatic Carcinoma
    Interventions:   Other: 18F-Fluoromisonidazole;   Drug: Cediranib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography
    Sponsors:   National Cancer Institute (NCI);   AstraZeneca
    Recruiting

  • Conditions:   Ovarian Granulosa Cell Tumor;   Ovarian Gynandroblastoma;   Ovarian Sertoli-Leydig Cell Tumor;   Ovarian Sex Cord Tumor With Annular Tubules;   Ovarian Sex Cord-Stromal Tumor;   Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types;   Ovarian Steroid Cell Tumor
    Interventions:   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Deleterious BARD1 Gene Mutation;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Deleterious BRIP1 Gene Mutation;   Deleterious EPCAM Gene Mutation;   Deleterious MLH1 Gene Mutation;   Deleterious MSH2 Gene Mutation;   Deleterious MSH6 Gene Mutation;   Deleterious PALB2 Gene Mutation;   Deleterious PMS2 Gene Mutation;   Deleterious RAD51C Gene Mutation;   Deleterious RAD51D Gene Mutation;   Hereditary Breast and Ovarian Cancer Syndrome;   Premenopausal
    Interventions:   Other: Laboratory Biomarker Analysis;   Procedure: Oophorectomy;   Other: Quality-of-Life Assessment;   Procedure: Salpingectomy;   Procedure: Salpingo-Oophorectomy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Ovarian Teratoma;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Pancreas Cancer;   Locally Advanced Pancreatic Cancer;   Pancreatic Adenocarcinoma
    Interventions:   Drug: EndoTAG-1;   Drug: Gemcitabine
    Sponsor:   SynCore Biotechnology Co., Ltd.
    Recruiting

  • Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal Low Grade Serous Adenocarcinoma;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   TP53 Negative
    Interventions:   Drug: Carboplatin;   Drug: Letrozole;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Endometrioid Adenocarcinoma;   Recurrent Cervical Carcinoma;   Stage I Uterine Corpus Cancer AJCC v7;   Stage I Vaginal Cancer AJCC v6 and v7;   Stage IA Uterine Corpus Cancer AJCC v7;   Stage IB Cervical Cancer AJCC v6 and v7;   Stage IB Uterine Corpus Cancer AJCC v7;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Uterine Corpus Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Cervical Cancer AJCC v6 and v7;   Stage III Uterine Corpus Cancer AJCC v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIA Cervical Cancer AJCC v6 and v7;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7
    Interventions:   Drug: Adavosertib;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Endometrial Clear Cell Adenocarcinoma;   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Endometrial Mixed Cell Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Endometrial Undifferentiated Carcinoma;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting

  • Conditions:   DCIS;   Ductal Carcinoma in Situ
    Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
    Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
    Recruiting

  • Conditions:   Advanced Solid Tumors (Part A/B/C/D);   Non-small Cell Lung Cancer (Part E);   Melanoma (Part E);   Squamous Cell Cancer of the Head and Neck (Part E);   Triple Negative Breast Cancer (Part F);   Adrenocortical Carcinoma (Part G);   Mesothelioma (Part G);   High-circulating Myeloid-derived Suppressor Cells (Part H)
    Interventions:   Drug: IPI-549;   Drug: Nivolumab
    Sponsor:   Infinity Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma
    Interventions:   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Procedure: Pancreatectomy
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Atypical Endometrial Hyperplasia;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
    Interventions:   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Device: Levonorgestrel-Releasing Intrauterine System
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting

  • Conditions:   Columnar Cell Variant Thyroid Gland Papillary Carcinoma;   Follicular Variant Thyroid Gland Papillary Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage III Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage III Thyroid Gland Follicular Carcinoma AJCC v7;   Stage III Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Hurthle Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lenvatinib;   Biological: Pembrolizumab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Biopsy, Fine-needle;   Pancreatic Neoplasm
    Interventions:   Diagnostic Test: Rapid on-site evaluation (ROSE);   Diagnostic Test: Histologic evaluation
    Sponsor:   Azienda Ospedaliera Universitaria Integrata Verona
    Recruiting

  • Conditions:   Cushing's Disease;   Acromegaly;   Neuroendocrine Tumors;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors;   Dumping Syndrome;   Prostate Cancer;   Melanoma Negative for bRAF;   Melanoma Negative for nRAS
    Interventions:   Drug: Pasireotide;   Drug: Cabergoline
    Sponsor:   Novartis Pharmaceuticals
    Recruiting